Author: "Schiavello E" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Schiavello E"' showing total 157 results

Start Over Author "Schiavello E"

157 results on '"Schiavello E"'

1. Posterior fossa syndrome in a population of children and young adults with medulloblastoma: a retrospective, multicenter Italian study on incidence and pathophysiology in a histologically homogeneous and consecutive series of 136 patients

Author: de Laurentis, C, Cristaldi, P, Rebora, P, Valsecchi, M, Biassoni, V, Schiavello, E, Carrabba, G, Trezza, A, Dimeco, F, Ferroli, P, Cinalli, G, Locatelli, M, Cenzato, M, Talamonti, G, Fontanella, M, Spena, G, Stefini, R, Bernucci, C, Bellocchi, S, Locatelli, D, Massimino, M, Giussani, C, de Laurentis C., Cristaldi P. M. F., Rebora P., Valsecchi M. G., Biassoni V., Schiavello E., Carrabba G. G., Trezza A., DiMeco F., Ferroli P., Cinalli G., Locatelli M., Cenzato M., Talamonti G., Fontanella M. M., Spena G., Stefini R., Bernucci C., Bellocchi S., Locatelli D., Massimino M., Giussani C., de Laurentis, C, Cristaldi, P, Rebora, P, Valsecchi, M, Biassoni, V, Schiavello, E, Carrabba, G, Trezza, A, Dimeco, F, Ferroli, P, Cinalli, G, Locatelli, M, Cenzato, M, Talamonti, G, Fontanella, M, Spena, G, Stefini, R, Bernucci, C, Bellocchi, S, Locatelli, D, Massimino, M, Giussani, C, de Laurentis C., Cristaldi P. M. F., Rebora P., Valsecchi M. G., Biassoni V., Schiavello E., Carrabba G. G., Trezza A., DiMeco F., Ferroli P., Cinalli G., Locatelli M., Cenzato M., Talamonti G., Fontanella M. M., Spena G., Stefini R., Bernucci C., Bellocchi S., Locatelli D., Massimino M., and Giussani C.
Abstract: Introduction: Posterior fossa syndrome (PFS) is a set of debilitating complications that can occur after surgery for posterior fossa tumors. This study aimed to assess the preoperative radiological and surgical risk factors for the onset of PFS in a histologically homogeneous population of children with medulloblastoma and compare it to a similar population of young adults. Methods: Included patients underwent posterior fossa surgery for medulloblastoma at 11 Italian neurosurgical wards (2003–2019) and were referred to Fondazione IRCCS Istituto Nazionale dei Tumori in Milan (INT) for postoperative treatments. We collected patients’ pre- and post-operative clinical, surgical and radiological data from the INT charts. To compare the distribution of variables, we used the Mann–Whitney and Fisher tests for continuous and categorical variables, respectively. Results: 136 patients (109 children and 27 young adults) were included in the study. Among children, 29 (27%) developed PFS, and all of them had tumors at midline site with invasion of the fourth ventricle. Radiological evidence of involvement of the right superior (39% versus 12%; p = 0.011) or middle cerebellar peduncles (52% versus 18%; p = 0.002) seemed more common in children who developed PFS. Young adults showed an expected lower incidence of PFS (4 out of 27; 15%), that may be due to anatomical, physiological and oncological elements. Conclusions: This study confirmed some factors known to be associated with PFS onset and shed light on other debated issues. Our findings enhance an already hypothesized role of cerebellar language lateralization. The analysis of a population of young adults may shed more light on the often-neglected existence of PFS in non-pediatric patients.
Published: 2022

2. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia

Author: Hurkmans, E. G. E., Klumpers, M. J., Dello Russo, Cinzia, De Witte, W., Guchelaar, H. -J., Gelderblom, H., Cleton-Jansen, A. -M., Vermeulen, S. H., Kaal, S., van der Graaf, W. T. A., Flucke, U., Gidding, C. E. M., Schreuder, H. W. B., de Bont, E. S. J. M., Caron, H. N., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., Mccowage, G., Nagabushan, S., Limaye, A., Rose, V., Catchpoole, D., Jorgensen, A. L., Barton, C., Delaney, L., Hawcutt, D. B., Pirmohamed, M., Pizer, B., Coenen, M. J. H., te Loo, D. M. W. M., Dello Russo C. (ORCID:0000-0002-2538-3832), Hurkmans, E. G. E., Klumpers, M. J., Dello Russo, Cinzia, De Witte, W., Guchelaar, H. -J., Gelderblom, H., Cleton-Jansen, A. -M., Vermeulen, S. H., Kaal, S., van der Graaf, W. T. A., Flucke, U., Gidding, C. E. M., Schreuder, H. W. B., de Bont, E. S. J. M., Caron, H. N., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., Mccowage, G., Nagabushan, S., Limaye, A., Rose, V., Catchpoole, D., Jorgensen, A. L., Barton, C., Delaney, L., Hawcutt, D. B., Pirmohamed, M., Pizer, B., Coenen, M. J. H., te Loo, D. M. W. M., and Dello Russo C. (ORCID:0000-0002-2538-3832)
Abstract: Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin chemotherapy. The aim of this study is to identify novel genetic variants that play a role in platinum-induced ototoxicity. Therefore, a genome-wide association study was performed in the Genetics of Childhood Cancer Treatment (GO-CAT) cohort (n = 261) and the United Kingdom Molecular Genetics of Adverse Drug Reactions in Children Study (United Kingdom MAGIC) cohort (n = 248). Results of both cohorts were combined in a meta-analysis. In primary analysis, patients with SIOP Boston Ototoxicity Scale grade ≥1 were considered cases, and patients with grade 0 were controls. Variants with a p-value <10-5 were replicated in previously published data by the PanCareLIFE cohort (n = 390). No genome-wide significant associations were found, but variants in TSPAN5, RBBP4P5, AC010090.1 and RNU6-38P were suggestively associated with platinum-induced ototoxicity. The lowest p-value was found for rs7671702 in TSPAN5 (odds ratio 2.0 (95% confidence interval 1.5-2.7), p-value 5.0 × 10-7). None of the associations were significant in the replication cohort, although the effect directions were consistent among all cohorts. Validation and functional understanding of these genetic variants could lead to more insights in the development of platinum-induced ototoxicity.
Published: 2023

3. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia

Author: Hurkmans, E.G.E., Klumpers, M.J., Dello Russo, C., Witte, W. de, Guchelaar, H.J., Gelderblom, H., Cleton-Jansen, A.M., Vermeulen, S.H., Kaal, S., Graaf, W.T.A. van der, Flucke, U., Gidding, C.E.M., Schreuder, H.W.B., Bont, E.S.J.M. de, Caron, H.N., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., McCowage, G., Nagabushan, S., Limaye, A., Rose, V., Catchpoole, D., Jorgensen, A.L., Barton, C., Delaney, L., Hawcutt, D.B., Pirmohamed, M., Pizer, B., Coenen, M.J.H., and Loo, D.M.W.M. te
Subjects: Pharmacology, Settore BIO/14 - FARMACOLOGIA, TSPAN5, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], cisplatin, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], ototoxicity, All institutes and research themes of the Radboud University Medical Center, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], carboplatin, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], childhood cancer, GWAS, Pharmacology (medical), Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract: Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin chemotherapy. The aim of this study is to identify novel genetic variants that play a role in platinum-induced ototoxicity. Therefore, a genome-wide association study was performed in the Genetics of Childhood Cancer Treatment (GO-CAT) cohort (n = 261) and the United Kingdom Molecular Genetics of Adverse Drug Reactions in Children Study (United Kingdom MAGIC) cohort (n = 248). Results of both cohorts were combined in a meta-analysis. In primary analysis, patients with SIOP Boston Ototoxicity Scale grade ≥1 were considered cases, and patients with grade 0 were controls. Variants with a p-value −5 were replicated in previously published data by the PanCareLIFE cohort (n = 390). No genome-wide significant associations were found, but variants in TSPAN5, RBBP4P5, AC010090.1 and RNU6-38P were suggestively associated with platinum-induced ototoxicity. The lowest p-value was found for rs7671702 in TSPAN5 (odds ratio 2.0 (95% confidence interval 1.5–2.7), p-value 5.0 × 10−7). None of the associations were significant in the replication cohort, although the effect directions were consistent among all cohorts. Validation and functional understanding of these genetic variants could lead to more insights in the development of platinum-induced ototoxicity.
Published: 2023

4. Quality of life in long-term survivors treated for metastatic medulloblastoma with a hyperfractionated accelerated radiotherapy (HART) strategy

Author: Veneroni, L., Boschetti, L., Barretta, F., Clerici, C. A., Simonetti, F., Schiavello, E., Biassoni, V., Spreafico, F., Gandola, L., Pecori, E., Diletto, B., Poggi, G., Gariboldi, F., Sensi, R., and Massimino, M.
Published: 2017
Full Text: View/download PDF

5. TREATING LYMPHOMA IN THE PANDEMIC ERA: WHAT WE LEARNED FROM OUR EXPERIENCE AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Author: Gattuso, G., primary, Biassoni, V., additional, Podda, M., additional, Meazza, C., additional, Chiaravalli, S., additional, Nigro, O., additional, Sironi, G., additional, Livellara, V., additional, Puma, N., additional, Bergamaschi, L., additional, Terenziani, M., additional, Spreafico, F., additional, Massimino, M., additional, and Schiavello, E., additional
Published: 2022
Full Text: View/download PDF

6. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

Author: Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., Frappaz D., Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, Frappaz, D, Massimino M., Sunyach M. P., Barretta F., Gandola L., Garegnani A., Pecori E., Spreafico F., Bonneville-Levard A., Meyronet D., Mottolese C., Boschetti L., Biassoni V., Schiavello E., Giussani C., Carrabba G., Diletto B., Pallotti F., Stefini R., Ferrari A., Terenziani M., Casanova M., Luksch R., Meazza C., Podda M., Chiaravalli S., Puma N., Bergamaschi L., Morosi C., Calareso G., Giangaspero F., Antonelli M., Buttarelli F. R., and Frappaz D.
Abstract: Introduction: Medulloblastoma is the most common malignant brain tumor in children, but accounts for only 1% of brain cancers in adults. For standard-risk pediatric medulloblastoma, current therapy includes craniospinal irradiation (CSI) at reduced doses (23.4 Gy) associated with chemotherapy. Whereas most same-stage adult patients are still given CSI at 36 Gy, with or without chemotherapy, we report here on our use of reduced-dose CSI associated with chemotherapy for older patients. Methods: We gathered non-metastatic patients over 18 years old (median age 28 years, range 18–48) with minimal or no residual disease after surgery, no negative histological subtypes, treated between 1996–2018 at the Centre Léon Bérard (Lyon) and the INT (Milano). A series of 54 children with similar tumors treated in Milano was used for comparison. Results: Forty-four adults were considered (median follow-up 101 months): 36 had 23.4 Gy of CSI, and 8 had 30.6 Gy, plus a boost to the posterior fossa/tumor bed; 43 had chemotherapy as all 54 children, who had a median 83-month follow-up. The PFS and OS were 82.2 ± 6.1% and 89 ± 5.2% at 5 years, and 78.5 ± 6.9% and 75.2 ± 7.8% at ten, not significantly different from those of the children. CSI doses higher than 23.4 Gy did not influence PFS. Female adult patients tended to have a better outcome than males. Conclusion: The results obtained in our combined series are comparable with, or even better than those obtained after high CSI doses, underscoring the need to reconsider this treatment in adults.
Published: 2020

7. Retrospective analysis of the clinical and radiological features of 94 consecutive DIPGs patients to investigate the factors determining the development of hydrocephalus and its impact on clinical status and survival

Author: Giussani, C, Guida, L, Biassoni, V, Schiavello, E, Carrabba, G, Trezza, A, Sganzerla, E, Massimino, M, Giussani C., Guida L., Biassoni V., Schiavello E., Carrabba G., Trezza A., Sganzerla E., Massimino M., Giussani, C, Guida, L, Biassoni, V, Schiavello, E, Carrabba, G, Trezza, A, Sganzerla, E, Massimino, M, Giussani C., Guida L., Biassoni V., Schiavello E., Carrabba G., Trezza A., Sganzerla E., and Massimino M.
Abstract: Purpose: There is no consensus in the literature about the impact of hydrocephalus on clinical course and overall survival of diffuse intrinsic pontine gliomas (DIPG) patients as well as about its specific treatment. Authors reviewed a series of DIPG patients to investigate factors related to the onset of hydrocephalus, its treatment, and its impact on clinical course and prognosis. Methods: A retrospective observational study was performed enrolling pediatric patients affected by DIPG from 2008 to 2018. Clinical and radiological charts were reviewed to find patients’ demographic, pathologic and radiologic features in hydrocephalic and non-hydrocephalic patients. In the hydrocephalus cohort, treatment strategy and its effectiveness and complications were analyzed. Results: Ninety-four pediatric patients were enrolled in the study. Patients who developed hydrocephalus showed significantly lesser maximum axial tumor areas than patients without hydrocephalus (respectively 6.5 cm2 vs 16.45 cm2, p < 0.005). Hydrocephalus developed in 33 patients (35%) with an onset interval of 5.24 ± 1.21 months (range 3.2–7.3). The majority of hydrocephalic patients (28 cases, 90%) were treated by ventriculoperitoneal shunt, the remaining 3 patients being treated by endoscopic third ventriculostomy. Mean overall survival was 16.6 months ± 20 months without significative difference between the groups. Conclusion: The onset of hydrocephalus occurs in the first moths of the disease story and found a negative correlation with tumor maximal axial diameter. Early treatment of hydrocephalus presents a very low complications rate with satisfying clinical outcome, as it allows the patients to continue the neurooncological therapies being a part of the treatment armamentarium instead of a palliative solution.
Published: 2020

8. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (cns) tumors and tropomyosin receptor kinase (trk) fusion.

Author: Lamoureux A.-A., Fisher M., Lemelle L., Pfaff E., Kramm C., De Wilde B., Kazanowska B., Hutter C., Pfister S.M., Sturm D., Jones D., Orbach D., Pierron G., Raskin S., Drilon A., Diamond E., Harada G., Zapotocky M., Ellezam B., Weil A.G., Venne D., Barritault M., Leblond P., Coltin H., Hammad R., Tabori U., Hawkins C., Hansford J.R., Meyran D., Erker C., McFadden K., Sato M., Gottardo N.G., Dholaria H., Noroxe D.S., Goto H., Ziegler D.S., Lin F.Y., Parsons D.W., Lindsay H., Wong T.-T., Liu Y.-L., Wu K.-S., Franson A.F., Hwang E., Aguilar-Bonilla A., Cheng S., Cacciotti C., Massimino M., Schiavello E., Wood P., Hoffman L.M., Cappellano A., Lassaletta A., Van Damme A., Llort A., Gerber N.U., Ceruso M.S., Bendel A.E., Skrypek M., Hamideh D., Mushtaq N., Walter A., Jabado N., Alsahlawi A., Farmer J.-P., Abadi C.C., Mueller S., Mazewski C., Aguilera D., Robison N., O'Halloran K., Abbou S., Berlanga P., Geoerger B., Ora I., Moertel C.L., Razis E.D., Vernadou A., Doz F., Laetsch T.W., Perreault S., Lamoureux A.-A., Fisher M., Lemelle L., Pfaff E., Kramm C., De Wilde B., Kazanowska B., Hutter C., Pfister S.M., Sturm D., Jones D., Orbach D., Pierron G., Raskin S., Drilon A., Diamond E., Harada G., Zapotocky M., Ellezam B., Weil A.G., Venne D., Barritault M., Leblond P., Coltin H., Hammad R., Tabori U., Hawkins C., Hansford J.R., Meyran D., Erker C., McFadden K., Sato M., Gottardo N.G., Dholaria H., Noroxe D.S., Goto H., Ziegler D.S., Lin F.Y., Parsons D.W., Lindsay H., Wong T.-T., Liu Y.-L., Wu K.-S., Franson A.F., Hwang E., Aguilar-Bonilla A., Cheng S., Cacciotti C., Massimino M., Schiavello E., Wood P., Hoffman L.M., Cappellano A., Lassaletta A., Van Damme A., Llort A., Gerber N.U., Ceruso M.S., Bendel A.E., Skrypek M., Hamideh D., Mushtaq N., Walter A., Jabado N., Alsahlawi A., Farmer J.-P., Abadi C.C., Mueller S., Mazewski C., Aguilera D., Robison N., O'Halloran K., Abbou S., Berlanga P., Geoerger B., Ora I., Moertel C.L., Razis E.D., Vernadou A., Doz F., Laetsch T.W., and Perreault S.
Abstract: BACKGROUND: TRK fusions are detected in less than 3% of CNS tumors. Given their rarity, there are limited data on the clinical course of these patients. METHOD(S): We contacted 166 oncology centers worldwide to retrieve data on patients with TRK fusion-driven CNS tumors. Data extracted included demographics, histopathology, NTRK gene fusion, treatment modalities and outcomes. Patients less than 18 years of age at diagnosis were included in this analysis. RESULT(S): Seventy-three pediatric patients with TRK fusion-driven primary CNS tumors were identified. Median age at diagnosis was 2.4 years (range 0.0-17.8) and 60.2 % were male. NTRK2 gene fusions were found in 37 patients (50.7%), NTRK1 and NTRK3 aberrations were detected in 19 (26.0%) and 17 (23.3%), respectively. Tumor types included 38 high-grade gliomas (HGG; 52.1%), 20 low-grade gliomas (LGG; 27.4%), 4 embryonal tumors (5.5%) and 11 others (15.1%). Median follow-up was 46.5 months (range 3-226). During the course of their disease, a total of 62 (84.9%) patients underwent surgery with a treatment intent, 50 (68.5%) patients received chemotherapy, 35 (47.9%) patients received radiation therapy, while 34 (46.6%) patients received NTRK inhibitors (3 as first line treatment). Twenty-four (32.9%) had no progression including 9 LGG (45%) and 9 HGG (23.6%). At last follow-up, only one (5.6%-18 evaluable) patient with LGG died compared to 11 with HGG (35.5%-31 evaluable). For LGG the median progression-free survival (PFS) after the first line of treatment was 17 months (95% CI: 0.0-35.5) and median overall survival (OS) was not reached. For patients with HGG the median PFS was 30 months (95% CI: 11.9-48.1) and median OS was 182 months (95% CI 20.2-343.8). CONCLUSION(S): We report the largest cohort of pediatric patients with TRK fusion-driven primary CNS tumors. These results will help us to better understand clinical evolution and compare outcomes with ongoing clinical trials.
Published: 2022

9. Contribution of common and rare genetic variants in CEP72 on vincristine-induced peripheral neuropathy in brain tumour patients

Author: Klumpers, M.J., Brand, A.C.A.M., Hakobjan, M.H., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., Gidding, C.E.M., Guchelaar, H.J., Loo, D.M.W.M. te, Coenen, M.J.H., Klumpers, M.J., Brand, A.C.A.M., Hakobjan, M.H., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., Gidding, C.E.M., Guchelaar, H.J., Loo, D.M.W.M. te, and Coenen, M.J.H.
Abstract: Item does not contain fulltext, AIMS: Studies implicated a role for a genetic variant in CEP72 in vincristine-induced peripheral neuropathy. This study aims to evaluate this association in a cohort of brain tumour patients, to perform a cross-disease meta-analysis and explore the protein-coding region of CEP72. METHODS: In total, 104 vincristine-treated brain tumour patients were genotyped for CEP72 rs924607, and sequenced for the protein-coding region. Data regarding patient and treatment characteristics, and peripheral neuropathy, were collected. Logistic regression and meta-analysis were performed for rs924607 replication. A weighted burden analysis was applied to evaluate impact of overall genetic variation in CEP72. RESULTS: Analysis of 24 cases and 80 controls did not show a significant association between CEP72 rs924607 and neuropathy (odds ratio, OR [95% confidence interval, CI] 2.076 [0.359-11.989], P = .414). When combined with 8 cohorts (1095 cancer patients), a significant increase in risk for neuropathy was found for patients with a TT genotype (OR [95% CI] 2.15 [1.35-3.43], P = .001). Additionally, a missense variant (rs12522955) was significantly associated (OR [95% CI] 2.3 [1.2-4.4], P = .041) and patients with severe neuropathy carried more impactful variants in CEP72 coding regions (P = .039). CONCLUSION: The association of CEP72 rs924607 in vincristine-induced neuropathy was not confirmed in a cohort of brain tumour patients, but did contribute to its suggested effect when combined in a cross-disease meta-analysis. The importance of other genetic variations in CEP72 on vincristine-induced neuropathy was demonstrated. This study contributes to evidence of the importance of genetic variants in CEP72 in development of vincristine-induced toxicity, and provides guidance for future prospective studies.
Published: 2022

10. HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.

Author: Lamoureux, A-A, Fisher, M, Lemelle, L, Pfaff, E, Kramm, C, De Wilde, B, Kazanowska, B, Hutter, C, Pfister, SM, Sturm, D, Jones, D, Orbach, D, Pierron, G, Raskin, S, Drilon, A, Diamond, E, Harada, G, Zapotocky, M, Ellezam, B, Weil, AG, Venne, D, Barritault, M, Leblond, P, Coltin, H, Hammad, R, Tabori, U, Hawkins, C, Hansford, JR, Meyran, D, Erker, C, McFadden, K, Sato, M, Gottardo, NG, Dholaria, H, Nørøxe, DS, Goto, H, Ziegler, DS, Lin, FY, Parsons, DW, Lindsay, H, Wong, T-T, Liu, Y-L, Wu, K-S, Franson, AF, Hwang, E, Aguilar-Bonilla, A, Cheng, S, Cacciotti, C, Massimino, M, Schiavello, E, Wood, P, Hoffman, LM, Cappellano, A, Lassaletta, A, Van Damme, A, Llort, A, Gerber, NU, Ceruso, MS, Bendel, AE, Skrypek, M, Hamideh, D, Mushtaq, N, Walter, A, Jabado, N, Alsahlawi, A, Farmer, J-P, Abadi, CC, Mueller, S, Mazewski, C, Aguilera, D, Robison, N, O’Halloran, K, Abbou, S, Berlanga, P, Geoerger, B, Øra, I, Moertel, CL, Razis, ED, Vernadou, A, Doz, F, Laetsch, TW, Perreault, S, Lamoureux, A-A, Fisher, M, Lemelle, L, Pfaff, E, Kramm, C, De Wilde, B, Kazanowska, B, Hutter, C, Pfister, SM, Sturm, D, Jones, D, Orbach, D, Pierron, G, Raskin, S, Drilon, A, Diamond, E, Harada, G, Zapotocky, M, Ellezam, B, Weil, AG, Venne, D, Barritault, M, Leblond, P, Coltin, H, Hammad, R, Tabori, U, Hawkins, C, Hansford, JR, Meyran, D, Erker, C, McFadden, K, Sato, M, Gottardo, NG, Dholaria, H, Nørøxe, DS, Goto, H, Ziegler, DS, Lin, FY, Parsons, DW, Lindsay, H, Wong, T-T, Liu, Y-L, Wu, K-S, Franson, AF, Hwang, E, Aguilar-Bonilla, A, Cheng, S, Cacciotti, C, Massimino, M, Schiavello, E, Wood, P, Hoffman, LM, Cappellano, A, Lassaletta, A, Van Damme, A, Llort, A, Gerber, NU, Ceruso, MS, Bendel, AE, Skrypek, M, Hamideh, D, Mushtaq, N, Walter, A, Jabado, N, Alsahlawi, A, Farmer, J-P, Abadi, CC, Mueller, S, Mazewski, C, Aguilera, D, Robison, N, O’Halloran, K, Abbou, S, Berlanga, P, Geoerger, B, Øra, I, Moertel, CL, Razis, ED, Vernadou, A, Doz, F, Laetsch, TW, and Perreault, S
Abstract: BACKGROUND: TRK fusions are detected in less than 3% of CNS tumors. Given their rarity, there are limited data on the clinical course of these patients. METHODS: We contacted 166 oncology centers worldwide to retrieve data on patients with TRK fusion-driven CNS tumors. Data extracted included demographics, histopathology, NTRK gene fusion, treatment modalities and outcomes. Patients less than 18 years of age at diagnosis were included in this analysis. RESULTS: Seventy-three pediatric patients with TRK fusion-driven primary CNS tumors were identified. Median age at diagnosis was 2.4 years (range 0.0–17.8) and 60.2 % were male. NTRK2 gene fusions were found in 37 patients (50.7%), NTRK1 and NTRK3 aberrations were detected in 19 (26.0%) and 17 (23.3%), respectively. Tumor types included 38 high-grade gliomas (HGG; 52.1%), 20 low-grade gliomas (LGG; 27.4%), 4 embryonal tumors (5.5%) and 11 others (15.1%). Median follow-up was 46.5 months (range 3-226). During the course of their disease, a total of 62 (84.9%) patients underwent surgery with a treatment intent, 50 (68.5%) patients received chemotherapy, 35 (47.9%) patients received radiation therapy, while 34 (46.6%) patients received NTRK inhibitors (3 as first line treatment). Twenty-four (32.9%) had no progression including 9 LGG (45%) and 9 HGG (23.6%). At last follow-up, only one (5.6%-18 evaluable) patient with LGG died compared to 11 with HGG (35.5%-31 evaluable). For LGG the median progression-free survival (PFS) after the first line of treatment was 17 months (95% CI: 0.0-35.5) and median overall survival (OS) was not reached. For patients with HGG the median PFS was 30 months (95% CI: 11.9-48.1) and median OS was 182 months (95% CI 20.2-343.8). CONCLUSIONS: We report the largest cohort of pediatric patients with TRK fusion-driven primary CNS tumors. These results will help us to better understand clinical evolution and compare outcomes with ongoing clinical trials.
Published: 2022

11. Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol

Author: Massimino, M., Barretta, F., Modena, P., Johann, P., Ferroli, P., Antonelli, M., Gandola, L., Garre, M. L., Bertin, D., Mastronuzzi, A., Mascarin, M., Quaglietta, L., Viscardi, E., Sardi, I., Ruggiero, Antonio, Boschetti, L., Giagnacovo, M., Biassoni, V., Schiavello, E., Chiapparini, L., Erbetta, A., Mussano, A., Giussani, C., Mura, R. M., Barra, S., Scarzello, G., Scimone, G., Carai, A., Giangaspero, F., Buttarelli, F. R., Ruggiero A. (ORCID:0000-0002-6052-3511), Massimino, M., Barretta, F., Modena, P., Johann, P., Ferroli, P., Antonelli, M., Gandola, L., Garre, M. L., Bertin, D., Mastronuzzi, A., Mascarin, M., Quaglietta, L., Viscardi, E., Sardi, I., Ruggiero, Antonio, Boschetti, L., Giagnacovo, M., Biassoni, V., Schiavello, E., Chiapparini, L., Erbetta, A., Mussano, A., Giussani, C., Mura, R. M., Barra, S., Scarzello, G., Scimone, G., Carai, A., Giangaspero, F., Buttarelli, F. R., and Ruggiero A. (ORCID:0000-0002-6052-3511)
Abstract: Background: More than 40% of patients with intracranial ependymoma need a salvage treatment within 5 years after diagnosis, and no standard treatment is available as yet. We report the outcome after first relapse of 64 patients treated within the 2nd AIEOP protocol. Methods: We considered relapse sites and treatments, that is, various combinations of complete/incomplete surgery, if followed by standard or hypofractionated radiotherapy (RT) ± chemotherapy (CT). Molecular analyses were available for 38/64 samples obtained at first diagnosis. Of the 64 cases, 55 were suitable for subsequent analyses. Results: The median follow-up was 147 months after diagnosis, 84 months after first relapse, 5-year EFS/OS were 26.2%/30.8% (median EFS/OS 13/32 months) after relapse. For patients with a local relapse (LR), the 5-year cumulative incidence of second LRs was 51.6%, with a 5-year event-specific probability of being LR-free of 40.0%. Tumor site/grade, need for shunting, age above/below 3 years, molecular subgroup at diagnosis, had no influence on outcomes. Due to variation in the RT dose/fractionation used and the subgroup sizes, it was not possible to assess the impact of the different RT modalities. Multivariable analyses identified completion of surgery, the absence of symptoms at relapse, and female sex as prognostically favorable. Tumors with a 1q gain carried a higher cumulative incidence of dissemination after first relapse. Conclusions: Survival after recurrence was significantly influenced by symptoms and completeness of surgery. Only a homogeneous protocol with well-posed, randomized questions could clarify the numerous issues, orient salvage treatment, and ameliorate prognosis for this group of patients.
Published: 2022

12. Cervicomedullary gliomas in pediatric age: a review of the literature and tertiary care center experience

Author: Trezza, A, de Laurentis, C, Biassoni, V, Carrabba, G, Schiavello, E, Canonico, F, Remida, P, Moretto, A, Massimino, M, Giussani, C, Carrabba, GG, Trezza, A, de Laurentis, C, Biassoni, V, Carrabba, G, Schiavello, E, Canonico, F, Remida, P, Moretto, A, Massimino, M, Giussani, C, and Carrabba, GG
Abstract: Introduction: Cervicomedullary gliomas (CMGs) are usually low-grade tumors often found in the pediatric age. Histological findings, treatments, and classification have been much the same for 40 years, although histological and molecular classifications have largely been developed for other pediatric CNS tumors. The management and treatment of pediatric CMG are still conducted by many authors according to their anatomical location and characteristics, independently from histology. Methods: We conducted a literature review in PubMed (Medline) to identify relevant contributions about pediatric CMG published until December 31, 2021. We also analyzed a series of 10 patients with CMG treated from 2006 to 2021 at IRCCS Istituto Nazionale dei Tumori. The aim of the present review was to see whether and how the diagnosis, treatment, and classification of CMGs in children have developed over time, especially in the context of molecular advancements, and to analyze our single-center experience in the last 15 years. Results: Thirty articles have been included in the review. Articles have been divided into two historical periods (1981-2000 and 2001-2021) and data from different series were analyzed to see how much the management and treatment of pediatric CMG have changed during years. Analysis of our series of 10 patients affected by CMG was also performed to compare it with the literature. Discussion: Management and classification of CMG in children have not dramatically changed during years. However, new insight from molecular diagnostics and target therapies and the development of radiological, neurophysiological, and radiotherapy techniques have updated treatment modalities in the last 20 years. Treatment modalities and their innovations have been reviewed and discussed. Further studies are needed to standardize and customize treatment protocols for these tumors.
Published: 2022

13. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia.

Author: Hurkmans, EGE, Klumpers, MJ, Dello Russo, C, De Witte, W, Guchelaar, H-J, Gelderblom, H, Cleton-Jansen, A-M, Vermeulen, SH, Kaal, S, van der Graaf, WTA, Flucke, U, Gidding, CEM, Schreuder, HWB, de Bont, ESJM, Caron, HN, Gattuso, G, Schiavello, E, Terenziani, M, Massimino, M, McCowage, G, Nagabushan, S, Limaye, A, Rose, V, Catchpoole, D, Jorgensen, AL, Barton, C, Delaney, L, Hawcutt, DB, Pirmohamed, M, Pizer, B, Coenen, MJH, Te Loo, DMWM, Hurkmans, EGE, Klumpers, MJ, Dello Russo, C, De Witte, W, Guchelaar, H-J, Gelderblom, H, Cleton-Jansen, A-M, Vermeulen, SH, Kaal, S, van der Graaf, WTA, Flucke, U, Gidding, CEM, Schreuder, HWB, de Bont, ESJM, Caron, HN, Gattuso, G, Schiavello, E, Terenziani, M, Massimino, M, McCowage, G, Nagabushan, S, Limaye, A, Rose, V, Catchpoole, D, Jorgensen, AL, Barton, C, Delaney, L, Hawcutt, DB, Pirmohamed, M, Pizer, B, Coenen, MJH, and Te Loo, DMWM
Abstract: Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin chemotherapy. The aim of this study is to identify novel genetic variants that play a role in platinum-induced ototoxicity. Therefore, a genome-wide association study was performed in the Genetics of Childhood Cancer Treatment (GO-CAT) cohort (n = 261) and the United Kingdom Molecular Genetics of Adverse Drug Reactions in Children Study (United Kingdom MAGIC) cohort (n = 248). Results of both cohorts were combined in a meta-analysis. In primary analysis, patients with SIOP Boston Ototoxicity Scale grade ≥1 were considered cases, and patients with grade 0 were controls. Variants with a p-value <10-5 were replicated in previously published data by the PanCareLIFE cohort (n = 390). No genome-wide significant associations were found, but variants in TSPAN5, RBBP4P5, AC010090.1 and RNU6-38P were suggestively associated with platinum-induced ototoxicity. The lowest p-value was found for rs7671702 in TSPAN5 (odds ratio 2.0 (95% confidence interval 1.5-2.7), p-value 5.0 × 10-7). None of the associations were significant in the replication cohort, although the effect directions were consistent among all cohorts. Validation and functional understanding of these genetic variants could lead to more insights in the development of platinum-induced ototoxicity.
Published: 2022

14. P06.01 Pediatric non-pontine diffuse midline glioma H3K27M mutant: a monoinstitutional experience

Author: Schiavello, E, primary, Biassoni, V, additional, De Cecco, L, additional, Pecori, E, additional, Filippo, S, additional, Gandola, L, additional, and Massimino, M, additional
Published: 2021
Full Text: View/download PDF

15. Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma

Author: Azzollini, J, Schiavello, E, Buttarelli, F, Clerici, C, Tizzoni, L, Vecchi, G, Capra, F, Pisati, F, Biassoni, V, Runza, L, Carrabba, G, Giangaspero, F, Massimino, M, Pensotti, V, Manoukian, S, Azzollini, Jacopo, Schiavello, Elisabetta, Buttarelli, Francesca Romana, Clerici, Carlo Alfredo, Tizzoni, Laura, Vecchi, Giovanna De, Capra, Fabio, Pisati, Federica, Biassoni, Veronica, Runza, Letterio, Carrabba, Giorgio, Giangaspero, Felice, Massimino, Maura, Pensotti, Valeria, Manoukian, Siranoush, Azzollini, J, Schiavello, E, Buttarelli, F, Clerici, C, Tizzoni, L, Vecchi, G, Capra, F, Pisati, F, Biassoni, V, Runza, L, Carrabba, G, Giangaspero, F, Massimino, M, Pensotti, V, Manoukian, S, Azzollini, Jacopo, Schiavello, Elisabetta, Buttarelli, Francesca Romana, Clerici, Carlo Alfredo, Tizzoni, Laura, Vecchi, Giovanna De, Capra, Fabio, Pisati, Federica, Biassoni, Veronica, Runza, Letterio, Carrabba, Giorgio, Giangaspero, Felice, Massimino, Maura, Pensotti, Valeria, and Manoukian, Siranoush
Abstract: Li-Fraumeni syndrome (LFS) is an autosomal dominant disorder caused by mutations in the TP53 gene, predisposing to a wide spectrum of early-onset cancers, including brain tumors. In medulloblastoma patients, the role of TP53 has been extensively investigated, though the prevalence of de novo mutations has not been addressed. We characterized TP53 mutations in a monocentric cohort of consecutive Sonic Hedgehog (SHH)-activated medulloblastoma patients. Germline testing was offered based on tumor p53 immunostaining positivity. Among 24 patients, three (12.5%) showed tumor p53 overexpression, of whom two consented to undergo germline testing and resulted as carriers of TP53 mutations. In the first case, family history was uneventful and the mutation was not found in either of the parents. The second patient, with a family history suggestive of LFS, unexpectedly resulted as a carrier of the mosaic mutation c.742=/C>T p.(Arg248=/Trp). The allele frequency was 26% in normal tissues and 42–77% in tumor specimens. Loss of heterozygosity (LOH) in the tumor was also confirmed. Notably, the mosaic case has been in complete remission for more than one year, while the first patient, as most TP53-mutated medulloblastoma cases from other cohorts, showed a severe and rapidly progressive disease. Our study reported the first TP53 mosaic mutation in medulloblastoma patients and confirmed the importance of germline testing in p53 overexpressed SHH-medulloblastoma, regardless of family history.
Published: 2020

16. Failure of peripheral blood stem cell mobilization procedure in paediatric patients eligible to autologous transplant: a survey of the Italian Pediatric Hematology Oncology Association: P569

Author: Cesaro, S., Calore, E., Schiavello, E., Nesi, F., Tintori, V., Luksch, R., Fagioli, F., Dallorso, S., Migliavacca, M., Balduzzi, A., Capolsini, I., Panizzolo, I., and Prête, A.
Published: 2011

17. 090 - TREATING LYMPHOMA IN THE PANDEMIC ERA: WHAT WE LEARNED FROM OUR EXPERIENCE AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Author: Gattuso, G., Biassoni, V., Podda, M., Meazza, C., Chiaravalli, S., Nigro, O., Sironi, G., Livellara, V., Puma, N., Bergamaschi, L., Terenziani, M., Spreafico, F., Massimino, M., and Schiavello, E.
Published: 2022
Full Text: View/download PDF

18. P14.77 Reduced dose craniospinal irradiation (CSI) is feasible for standard risk adult medulloblastoma (MBL) patients similarly to pediatric population

Author: Massimino, M, primary, Sunyach, M, additional, Gandola, L, additional, Pecori, E, additional, Spreafico, F, additional, Bonneville Levard, A, additional, Biassoni, V, additional, Schiavello, E, additional, Diletto, B, additional, Stefini, R, additional, and Frappaz, D, additional
Published: 2019
Full Text: View/download PDF

19. PO-0872 Hematological toxicity of 3DCRT and VMAT craniospinal irradiatiation in pediatric medulloblastoma

Author: Diletto, B., primary, Pecori, E., additional, Alessandro, O., additional, Meroni, S., additional, Giandini, T., additional, Stucchi, C., additional, Cavatorta, C., additional, Schiavello, E., additional, Biassoni, V., additional, Massimino, M., additional, Pignoli, E., additional, and Gandola, L., additional
Published: 2019
Full Text: View/download PDF

20. 50. Retrospective study of late radiation damages after focal radiotherapy for childhood brain tumors

Author: Meroni, S., primary, Cavatorta, C., additional, Lecchi, M., additional, Montin, E., additional, Oprandi, C., additional, Pecori, E., additional, Spreafico, F., additional, Diletto, B., additional, Biassoni, V., additional, Schiavello, E., additional, Arrigoni, F., additional, Poggi, G., additional, Massimino, M., additional, Mainardi, L., additional, Verderio, P., additional, Pignoli, E., additional, and Gandola, L., additional
Published: 2018
Full Text: View/download PDF

21. Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up

Author: Massimino, M, Barretta, F, Modena, P, Giangaspero, F, Chiapparini, L, Erbetta, A, Boschetti, L, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Viscardi, E, Scarzello, G, Mascarin, M, Quaglietta, L, Cinalli, G, Genitori, L, Peretta, P, Mussano, A, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Tornesello, A, La Spina, M, Buttarelli, F, Ruggiero, A, Caldarelli, M, Poggi, G, Gandola, L, Garrè, ML, Marras, CE, Buttarelli, FR, Massimino, M, Barretta, F, Modena, P, Giangaspero, F, Chiapparini, L, Erbetta, A, Boschetti, L, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Viscardi, E, Scarzello, G, Mascarin, M, Quaglietta, L, Cinalli, G, Genitori, L, Peretta, P, Mussano, A, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Tornesello, A, La Spina, M, Buttarelli, F, Ruggiero, A, Caldarelli, M, Poggi, G, Gandola, L, Garrè, ML, Marras, CE, and Buttarelli, FR
Abstract: Purpose: The aims of patients’ radiological surveillance are to: ascertain relapse; apply second-line therapy; accrue patients in phase 1/2 protocols if second-line therapy is not standardized/curative; and assess/treat iatrogenic effects. To lessen the emotional and socioeconomic burdens for patients and families, we ideally need to establish whether scheduled radiological surveillance gives patients a better outcome than waiting for symptoms and signs to appear. Methods: We analyzed a prospective series of 160 newly-diagnosed and treated pediatric/adolescent patients with intracranial ependymoma, comparing patients with recurrent disease identified on scheduled MRI (the RECPT group; 34 cases) with those showing signs/symptoms of recurrent disease (the SYMPPT group; 16 cases). The median follow-up was 67 months. Results: No significant differences emerged between the two groups in terms of gender, age, tumor grade/site, shunting, residual disease, or type of relapse (local, distant, or concomitant). The time to relapse (median 19 months; range 5–104) and the MRI follow-up intervals did not differ between the SYMPPT and RECPT groups. The presence of signs/symptoms was an unfavorable factor for overall survival (OS) after recurrence (5-year OS: 8% vs. 37%, p = 0.001). On multivariable analysis, an adjusted model confirmed a significantly worse OS in the SYMPPT than in the RECPT patients. Conclusions: Symptomatic relapses carried a significantly worse survival for ependymoma patients than recurrences detected by MRI alone. It would therefore be desirable to identify recurrences before symptoms develop. Radiological follow-up should be retained in ependymoma patient surveillance because there is a chance of salvage treatment for relapses found on MRI
Published: 2018

22. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Author: Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, Gandola, L., Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, and Gandola, L.
Abstract: Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
Published: 2016

23. PO-0856: Clinical and dosimetric issues of VMAT craniospinal irradiation for paediatric medulloblastoma

Author: Meroni, S., primary, Giandini, T., additional, Diletto, B., additional, Pecori, E., additional, Chiruzzi, C., additional, Biassoni, V., additional, Schiavello, E., additional, Sreafico, F., additional, Massimino, M., additional, Pignoli, E., additional, and Gandola, L., additional
Published: 2016
Full Text: View/download PDF

24. OC-0346: Pediatric diffuse intrinsic pontine glioma re-irradiation: better survival and better time

Author: Gandola, L., primary, Pecori, E., additional, Biassoni, V., additional, Diletto, B., additional, Schiavello, E., additional, Meroni, S., additional, Spreafico, F., additional, Pignoli, E., additional, and Massimino, M., additional
Published: 2016
Full Text: View/download PDF

25. Management of breast cancer after Hodgkin’s lymphoma and paediatric cancer

Author: Terenziani, M., primary, Massimino, M., additional, Magazzù, D., additional, Gandola, L., additional, Capri, G., additional, Carcangiu, M.L., additional, Catania, S., additional, Di Russo, A., additional, Gennaro, M., additional, Meazza, C., additional, Podda, M., additional, Schiavello, E., additional, and Valagussa, P., additional
Published: 2015
Full Text: View/download PDF

26. EP-1531: Image registration framework to investigate children neurocognitive outcome after focal brain irradiation

Author: Meroni, S., primary, Montin, E., additional, Arrigoni, F., additional, Cavatorta, C., additional, Poggi, G., additional, Oprandi, C., additional, Pecori, E., additional, Schiavello, E., additional, Diletto, B., additional, Massimino, M., additional, Mainardi, L., additional, Pignoli, E., additional, and Gandola, L., additional
Published: 2015
Full Text: View/download PDF

27. O10.10 * RESULTS OF NIMOTUZUMAB AND VINORELBINE, RADIATION AND RE-IRRADIATION FOR DIFFUSE PONTINE GLIOMA IN CHILDHOOD

Author: Massimino, M., primary, Biassoni, V., additional, Miceli, R., additional, Schiavello, E., additional, Warmuth-Metz, M., additional, Modena, P., additional, Giangaspero, F., additional, Spreafico, F., additional, Bach, F., additional, and Gandola, L., additional
Published: 2014
Full Text: View/download PDF

28. QUALITY OF LIFE/AFTERCARE

Author: Strobel, K., primary, Simpson, P., additional, Donohoue, P., additional, Firat, S., additional, Jogal, S., additional, Lai, J.-S., additional, Beaumont, J., additional, Goldman, S., additional, Huang, C., additional, Barrera, M., additional, Rokeach, A., additional, Hancock, K., additional, Cataudella, D., additional, Schulte, F., additional, Chung, J., additional, Bartels, U., additional, Janzen, L., additional, Sung, L., additional, Strother, D., additional, Hukin, J., additional, Downie, A., additional, Zelcer, S., additional, Atenafu, E., additional, Schiavello, E., additional, Biassoni, V., additional, Meazza, C., additional, Podda, M., additional, Massimino, M., additional, Wells, E. M., additional, Ullrich, N. J., additional, Seidel, K., additional, Leisenring, W., additional, Sklar, C., additional, Armstrong, G. T., additional, Diller, L., additional, King, A., additional, krull, K., additional, Neglia, J. P., additional, Stovall, M., additional, Whelan, K., additional, Robison, L. L., additional, Packer, R. J., additional, Remes, T., additional, Harila-Saari, A., additional, Suo-Palosaari, M., additional, Lahteenmaki, P., additional, Arikoski, P., additional, Riikonen, P., additional, Rantala, H., additional, Ojaniemi, M., additional, Bull, K., additional, Kennedy, C., additional, Bailey, S., additional, Ellison, D., additional, Clifford, S., additional, Dembowska-Baginska, B., additional, Brozyna, A., additional, Drogosiewicz, M., additional, Perek-Polnik, M., additional, Swieszkowska, E., additional, Filipek, I., additional, Tarasinska, M., additional, Korzeniewska, J., additional, Perek, D., additional, Salgado, D., additional, Nunes, S., additional, Pereira, P., additional, Vinhais, S., additional, Salih, S., additional, Elsarrag, S., additional, Prange, E., additional, Contreas, K., additional, Possin, P., additional, Frierdich, S., additional, Eickhoff, J., additional, Puccetti, D., additional, Ladas, E., additional, Buck, C., additional, Arbit, N., additional, Gudrunardottir, T., additional, Lannering, B., additional, Remke, M., additional, Taylor, M. D., additional, Keating, R. F., additional, Stapleton, S., additional, Flanary, J., additional, Hamblin, F., additional, Amankwah, E., additional, Ghazarian, S., additional, Jagt, C. T., additional, van de Wetering, M., additional, Schouten-van Meeteren, A. Y. N., additional, Nowinski, C., additional, Hartsell, W., additional, Chang, J. H.-C., additional, Cella, D., additional, Krishna, U., additional, Nagrulkar, A., additional, Takle, M., additional, Kannan, S., additional, Gupta, T., additional, Jalali, R., additional, Northman, L., additional, Morris, M., additional, Ross, S., additional, Guo, D., additional, Chordas, C., additional, Liptak, C., additional, Delaney, B., additional, Ullrich, N., additional, Manley, P., additional, Avula, S., additional, Pizer, B., additional, Ong, C. C., additional, Harave, S., additional, Mallucci, C., additional, Kumar, R., additional, Margol, A., additional, Finlay, J., additional, Dhall, G., additional, Robison, N., additional, Krieger, M., additional, Kiehna, E., additional, Coates, T., additional, Nelson, M., additional, Grimm, J., additional, Evans, A., additional, Nelson, M. B., additional, Britt, B., additional, Cooksey, R., additional, Wu, S., additional, Gode, A., additional, Klesse, L., additional, Oden, J., additional, Vega, G., additional, Gargan, L., additional, Bowers, D., additional, Madden, J. R., additional, Prince, E., additional, Zeitler, P., additional, Foreman, N. K., additional, and Liu, A. K., additional
Published: 2014
Full Text: View/download PDF

29. EPENDYMOMA

Author: Hoffman, L. M., primary, Donson, A. M., additional, Nakachi, I., additional, Griesinger, A. M., additional, Birks, D. K., additional, Amani, V., additional, Hemenway, M. S., additional, Liu, A. K., additional, Wang, M., additional, Hankinson, T. C., additional, Handler, M. H., additional, Foreman, N. K., additional, Zakrzewska, M., additional, Zakrzewski, K., additional, Fendler, W., additional, Stefanczyk, L., additional, Liberski, P. P., additional, Massimino, M., additional, Gandola, L., additional, Ferroli, P., additional, Valentini, L., additional, Biassoni, V., additional, Garre, M. L., additional, Sardi, I., additional, Genitori, L., additional, Giussani, C., additional, Massimi, L., additional, Bertin, D., additional, Mussano, A., additional, Viscardi, E., additional, Modena, P., additional, Mastronuzzi, A., additional, Barra, S., additional, Scarzello, G., additional, Cinalli, G., additional, Peretta, P., additional, Giangaspero, F., additional, Boschetti, L., additional, Schiavello, E., additional, Calareso, G., additional, Antonelli, M., additional, Pecori, E., additional, Di Meco, F., additional, Migliorati, R., additional, Taborelli, A., additional, Witt, H., additional, Sill, M., additional, Wani, K., additional, Mack, S. C., additional, Capper, D., additional, Pajtler, K., additional, Lambert, S., additional, Tzaridis, T., additional, Milde, T., additional, Northcott, P. A., additional, Kulozik, A. E., additional, Witt, O., additional, Collins, V. P., additional, Ellison, D. W., additional, Taylor, M. D., additional, Kool, M., additional, Jones, D. T. W., additional, Korshunov, A., additional, Ken, A., additional, Pfister, S. M., additional, Makino, K., additional, Nakamura, H., additional, Kuroda, J.-i., additional, Kuratsu, J.-i., additional, Toledano, H., additional, Margolin, Y., additional, Ohali, A., additional, Michowiz, S., additional, Johann, P., additional, Tabori, U., additional, Walker, E., additional, Hawkins, C., additional, Taylor, M., additional, Yaniv, I., additional, Avigad, S., additional, Hoffman, L., additional, Plimpton, S. R., additional, Stence, N. V., additional, Vibhakar, R., additional, Lourdusamy, A., additional, Rahman, R., additional, Ward, J., additional, Rogers, H., additional, Grundy, R., additional, Punchihewa, C., additional, Lee, R., additional, Lin, T., additional, Orisme, W., additional, Dalton, J., additional, Aronica, E., additional, Smith, A., additional, Gajjar, A., additional, Onar, A., additional, Pounds, S., additional, Tatevossian, R., additional, Merchant, T., additional, Ellison, D., additional, Parker, M., additional, Mohankumar, K., additional, Weinlich, R., additional, Phoenix, T., additional, Thiruvenkatam, R., additional, White, E., additional, Gupta, K., additional, Boop, F., additional, Ding, L., additional, Mardis, E., additional, Wilson, R., additional, Downing, J., additional, Gilbertson, R., additional, Speed, D., additional, Gould, T., additional, Consortium, t. I. E., additional, Hoffman, L. M., additional, Griesinger, A., additional, Donson, A., additional, Birks, D., additional, Ohe, N., additional, Yano, H., additional, Nakayama, N., additional, Iwama, T., additional, Wright, K., additional, Hassall, T., additional, Bowers, D. C., additional, Crawford, J., additional, Bendel, A., additional, Fisher, P. G., additional, Klimo, P., additional, Armstrong, G., additional, Qaddoumi, I., additional, Robinson, G., additional, Wetmore, C., additional, Broniscer, A., additional, Chapman, R., additional, Mayne, C., additional, Duane, H., additional, Kilday, J.-P., additional, Coyle, B., additional, Graul-Conroy, A., additional, Hartsell, W., additional, Bragg, T., additional, Goldman, S., additional, Rebsamen, S., additional, Puccetti, D., additional, Salamat, S., additional, Patel, N. J., additional, Gomi, A., additional, Oguma, H., additional, Hayase, T., additional, Kawahara, Y., additional, Yagi, M., additional, Morimoto, A., additional, Wilbur, C., additional, Dunham, C., additional, Mabbott, D., additional, Carret, A.-S., additional, Lafay-Cousin, L., additional, McNeely, P. D., additional, Eisenstat, D., additional, Wilson, B., additional, Johnston, D., additional, Hukin, J., additional, Mynarek, M., additional, Kortmann, R. D., additional, Kaatsch, P., additional, Pietsch, T., additional, Timmermann, B., additional, Fleischhack, G., additional, Benesch, M., additional, Friedrich, C., additional, von Bueren, A. O., additional, Gerber, N. U., additional, Muller, K., additional, Tippelt, S., additional, Warmuth-Metz, M., additional, Rutkowski, S., additional, von Hoff, K., additional, Murugesan, M. K., additional, Poppleton, H., additional, Currle, S., additional, Kranenburg, T., additional, Eden, C., additional, Boulos, N., additional, Dapper, J., additional, Patel, Y., additional, Freeman, B., additional, Shelat, A., additional, Stewart, C., additional, Guy, R., additional, Adamski, J., additional, Huang, A., additional, Bartels, U., additional, Ramaswamy, V., additional, Krishnatry, R., additional, Laperriere, N., additional, Bouffet, E., additional, Araki, A., additional, Chocholous, M., additional, Gojo, J., additional, Dorfer, C., additional, Czech, T., additional, Dieckmann, K., additional, Slavc, I., additional, Haberler, C., additional, Doerner, E., additional, Muehlen, A. z., additional, Kortmann, R., additional, von Buehren, A., additional, Ottensmeier, H., additional, Resch, A., additional, Kwiecien, R., additional, Faldum, A., additional, Kuehl, J., additional, Sabnis, D., additional, Storer, L., additional, Simmonds, L., additional, Blackburn, S., additional, Lowe, J., additional, Kerr, I., additional, Wohlers, I., additional, Goschzik, T., additional, Dreschmann, V., additional, Denkhaus, D., additional, Rahmann, S., additional, Klein-Hitpass, L., additional, Iglesias, M. J. L., additional, Riet, F. G., additional, Dhermain, F. D., additional, Canale, S., additional, Dufour, C., additional, Rose, C. S., additional, Puget, S., additional, Grill, J., additional, Bolle, S., additional, Parkes, J., additional, Davidson, A., additional, Figaji, A., additional, Pillay, K., additional, Kilborn, T., additional, Padayachy, L., additional, Hendricks, M., additional, Van Eyssen, A., additional, Piccinin, E., additional, Lorenzetto, E., additional, Brenca, M., additional, Aldape, K., additional, Cho, Y.-J., additional, Weiss, W., additional, Phillips, J., additional, Jabado, N., additional, Mora, J., additional, Fan, X., additional, Jung, S., additional, Lee, J. Y., additional, Zitterbart, K., additional, French, P., additional, Kros, J. M., additional, Hauser, P., additional, Faria, C., additional, and Pfister, S., additional
Published: 2014
Full Text: View/download PDF

30. HIGH GRADE GLIOMAS AND DIPG

Author: Classen, C. F., primary, William, D., additional, Linnebacher, M., additional, Farhod, A., additional, Kedr, W., additional, Elsabe, B., additional, Fadel, S., additional, Van Gool, S., additional, De Vleeschouwer, S., additional, Koks, C., additional, Garg, A., additional, Ehrhardt, M., additional, Riva, M., additional, Agostinis, P., additional, Graf, N., additional, Yao, T.-W., additional, Yoshida, Y., additional, Zhang, J., additional, Ozawa, T., additional, James, D., additional, Nicolaides, T., additional, Kebudi, R., additional, Cakir, F. B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Darendeliler, E., additional, Al-Kofide, A., additional, Al-Shail, E., additional, Khafaga, Y., additional, Al-Hindi, H., additional, Dababo, M., additional, Haq, A. U., additional, Anas, M., additional, Barria, M. G., additional, Siddiqui, K., additional, Hassounah, M., additional, Ayas, M., additional, van Zanten, S. V., additional, Jansen, M., additional, van Vuurden, D., additional, Huisman, M., additional, Vugts, D., additional, Hoekstra, O., additional, van Dongen, G., additional, Kaspers, G., additional, Cockle, J., additional, Ilett, E., additional, Scott, K., additional, Bruning-Richardson, A., additional, Picton, S., additional, Short, S., additional, Melcher, A., additional, Benesch, M., additional, Warmuth-Metz, M., additional, von Bueren, A. O., additional, Hoffmann, M., additional, Pietsch, T., additional, Kortmann, R.-D., additional, Eyrich, M., additional, Rutkowski, S., additional, Fruhwald, M. C., additional, Faber, J., additional, Kramm, C., additional, Porkholm, M., additional, Valanne, L., additional, Lonnqvist, T., additional, Holm, S., additional, Lannering, B., additional, Riikonen, P., additional, Wojcik, D., additional, Sehested, A., additional, Clausen, N., additional, Harila-Saari, A., additional, Schomerus, E., additional, Thorarinsdottir, H. K., additional, Lahteenmaki, P., additional, Arola, M., additional, Thomassen, H., additional, Saarinen-Pihkala, U. M., additional, Kivivuori, S.-M., additional, Buczkowicz, P., additional, Hoeman, C., additional, Rakopoulos, P., additional, Pajovic, S., additional, Morrison, A., additional, Bouffet, E., additional, Bartels, U., additional, Becher, O., additional, Hawkins, C., additional, Gould, T. W. A., additional, Rahman, C. V., additional, Smith, S. J., additional, Barrett, D. A., additional, Shakesheff, K. M., additional, Grundy, R. G., additional, Rahman, R., additional, Barua, N., additional, Cronin, D., additional, Gill, S., additional, Lowisl, S., additional, Hochart, A., additional, Maurage, C.-A., additional, Rocourt, N., additional, Vinchon, M., additional, Kerdraon, O., additional, Escande, F., additional, Grill, J., additional, Pick, V. K., additional, Leblond, P., additional, Burzynski, G., additional, Janicki, T., additional, Burzynski, S., additional, Marszalek, A., additional, Ramani, N., additional, Zaky, W., additional, Kannan, G., additional, Morani, A., additional, Sandberg, D., additional, Ketonen, L., additional, Maher, O., additional, Corrales-Medina, F., additional, Meador, H., additional, Khatua, S., additional, Brassesco, M., additional, Delsin, L., additional, Roberto, G., additional, Silva, C., additional, Ana, L., additional, Rego, E., additional, Scrideli, C., additional, Umezawa, K., additional, Tone, L., additional, Kim, S. J., additional, Kim, C.-Y., additional, Kim, I.-A., additional, Han, J. H., additional, Choi, B.-S., additional, Ahn, H. S., additional, Choi, H. S., additional, Haque, F., additional, Layfield, R., additional, Grundy, R., additional, Gandola, L., additional, Pecori, E., additional, Biassoni, V., additional, Schiavello, E., additional, Chiruzzi, C., additional, Spreafico, F., additional, Modena, P., additional, Bach, F., additional, Pignoli, E., additional, Massimino, M., additional, Drogosiewicz, M., additional, Dembowska-Baginska, B., additional, Jurkiewicz, E., additional, Filipek, I., additional, Perek-Polnik, M., additional, Swieszkowska, E., additional, Perek, D., additional, Bender, S., additional, Jones, D. T., additional, Warnatz, H.-J., additional, Hutter, B., additional, Zichner, T., additional, Gronych, J., additional, Korshunov, A., additional, Eils, R., additional, Korbel, J. O., additional, Yaspo, M.-L., additional, Lichter, P., additional, Pfister, S. M., additional, Yadavilli, S., additional, Becher, O. J., additional, Kambhampati, M., additional, Packer, R. J., additional, Nazarian, J., additional, Lechon, F. C., additional, Fowkes, L., additional, Khabra, K., additional, Martin-Retortillo, L. M., additional, Marshall, L. V., additional, Vaidya, S., additional, Koh, D.-M., additional, Leach, M. O., additional, Pearson, A. D., additional, Zacharoulis, S., additional, Schrey, D., additional, Barone, G., additional, Panditharatna, E., additional, Stampar, M., additional, Siu, A., additional, Gordish-Dressman, H., additional, Devaney, J., additional, Hwang, E. I., additional, Chung, A. H., additional, Mittapalli, R. K., additional, Elmquist, W. F., additional, Castel, D., additional, Debily, M.-A., additional, Philippe, C., additional, Truffaux, N., additional, Taylor, K., additional, Calmon, R., additional, Boddaert, N., additional, Le Dret, L., additional, Saulnier, P., additional, Lacroix, L., additional, Mackay, A., additional, Jones, C., additional, Puget, S., additional, Sainte-Rose, C., additional, Blauwblomme, T., additional, Varlet, P., additional, Entz-Werle, N., additional, Maugard, C., additional, Bougeard, G., additional, Nguyen, A., additional, Chenard, M. P., additional, Schneider, A., additional, Gaub, M. P., additional, Tsoli, M., additional, Vanniasinghe, A., additional, Luk, P., additional, Dilda, P., additional, Haber, M., additional, Hogg, P., additional, Ziegler, D., additional, Simon, S., additional, Monje, M., additional, Gurova, K., additional, Gudkov, A., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Zamecnik, J., additional, Kyncl, M., additional, Tichy, M., additional, Puchmajerova, A., additional, Stary, J., additional, Sumerauer, D., additional, Boult, J., additional, Vinci, M., additional, Perryman, L., additional, Box, G., additional, Jury, A., additional, Popov, S., additional, Ingram, W., additional, Eccles, S., additional, Robinson, S., additional, Emir, S., additional, Demir, H. A., additional, Bayram, C., additional, Cetindag, F., additional, Kabacam, G. B., additional, Fettah, A., additional, Li, J., additional, Jamin, Y., additional, Cummings, C., additional, Bamber, J., additional, Sinkus, R., additional, Nandhabalan, M., additional, Bjerke, L., additional, Burford, A., additional, von Bueren, A., additional, Baudis, M., additional, Clarke, P., additional, Collins, I., additional, Workman, P., additional, Olaciregui, N., additional, Mora, J., additional, Carcaboso, A., additional, Bullock, A., additional, Alonso, M., additional, de Torres, C., additional, Cruz, O., additional, Pencreach, E., additional, Moussalieh, F. M., additional, Guenot, D., additional, Namer, I., additional, Pollack, I., additional, Jakacki, R., additional, Butterfield, L., additional, Hamilton, R., additional, Panigrahy, A., additional, Potter, D., additional, Connelly, A., additional, Dibridge, S., additional, Whiteside, T., additional, Okada, H., additional, Ahsan, S., additional, Raabe, E., additional, Haffner, M., additional, Warren, K., additional, Quezado, M., additional, Ballester, L., additional, Eberhart, C., additional, Rodriguez, F., additional, Ramachandran, C., additional, Nair, S., additional, Quirrin, K.-W., additional, Khatib, Z., additional, Escalon, E., additional, Melnick, S., additional, Classen, C. F., additional, Hofmann, M., additional, Schmid, I., additional, Simon, T., additional, Maass, E., additional, Russo, A., additional, Fleischhack, G., additional, Becker, M., additional, Hauch, H., additional, Sander, A., additional, Grasso, C., additional, Berlow, N., additional, Liu, L., additional, Davis, L., additional, Huang, E., additional, Woo, P., additional, Tang, Y., additional, Ponnuswami, A., additional, Chen, S., additional, Huang, Y., additional, Hutt-Cabezas, M., additional, Dret, L., additional, Meltzer, P., additional, Mao, H., additional, Abraham, J., additional, Fouladi, M., additional, Svalina, M. N., additional, Wang, N., additional, Hulleman, E., additional, Li, X.-N., additional, Keller, C., additional, Spellman, P. T., additional, Pal, R., additional, Jansen, M. H. A., additional, Sewing, A. C. P., additional, Lagerweij, T., additional, Vuchts, D. J., additional, van Vuurden, D. G., additional, Caretti, V., additional, Wesseling, P., additional, Kaspers, G. J. L., additional, Cohen, K., additional, Pearl, M., additional, Kogiso, M., additional, Zhang, L., additional, Qi, L., additional, Lindsay, H., additional, Lin, F., additional, Berg, S., additional, Muscal, J., additional, Amayiri, N., additional, Tabori, U., additional, Campbel, B., additional, Bakry, D., additional, Aronson, M., additional, Durno, C., additional, Gallinger, S., additional, Malkin, D., additional, Qaddumi, I., additional, Musharbash, A., additional, Swaidan, M., additional, Al-Hussaini, M., additional, Shandilya, S., additional, McCully, C., additional, Murphy, R., additional, Akshintala, S., additional, Cole, D., additional, Macallister, R. P., additional, Cruz, R., additional, Widemann, B., additional, Salloum, R., additional, Smith, A., additional, Glaunert, M., additional, Ramkissoon, A., additional, Peterson, S., additional, Baker, S., additional, Chow, L., additional, Sandgren, J., additional, Pfeifer, S., additional, Popova, S., additional, Alafuzoff, I., additional, de Stahl, T. D., additional, Pietschmann, S., additional, Kerber, M. J., additional, Zwiener, I., additional, Henke, G., additional, Muller, K., additional, Sieow, N. Y.-F., additional, Hoe, R. H. M., additional, Tan, A. M., additional, Chan, M. Y., additional, Soh, S. Y., additional, Burrell, K., additional, Chornenkyy, Y., additional, Remke, M., additional, Golbourn, B., additional, Barzczyk, M., additional, Taylor, M., additional, Rutka, J., additional, Dirks, P., additional, Zadeh, G., additional, Agnihotri, S., additional, Hashizume, R., additional, Ihara, Y., additional, Andor, N., additional, Chen, X., additional, Lerner, R., additional, Huang, X., additional, Tom, M., additional, Solomon, D., additional, Mueller, S., additional, Petritsch, C., additional, Zhang, Z., additional, Gupta, N., additional, Waldman, T., additional, Dujua, A., additional, Co, J., additional, Hernandez, F., additional, Doromal, D., additional, Hegde, M., additional, Wakefield, A., additional, Brawley, V., additional, Grada, Z., additional, Byrd, T., additional, Chow, K., additional, Krebs, S., additional, Heslop, H., additional, Gottschalk, S., additional, Yvon, E., additional, Ahmed, N., additional, Cornilleau, G., additional, Paulsson, J., additional, Andreiuolo, F., additional, Guerrini-Rousseau, L., additional, Geoerger, B., additional, Vassal, G., additional, Ostman, A., additional, Parsons, D. W., additional, Trevino, L. R., additional, Gao, F., additional, Shen, X., additional, Hampton, O., additional, Kosigo, M., additional, Baxter, P. A., additional, Su, J. M., additional, Chintagumpala, M., additional, Dauser, R., additional, Adesina, A., additional, Plon, S. E., additional, Wheeler, D. A., additional, Lau, C. C., additional, Gielen, G., additional, Muehlen, A. z., additional, Kwiecien, R., additional, Wolff, J., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Fangusaro, J., additional, Kieran, M., additional, Fontebasso, A., additional, Papillon-Cavanagh, S., additional, Schwartzentruber, J., additional, Nikbakht, H., additional, Gerges, N., additional, Fiset, P.-O., additional, Bechet, D., additional, Faury, D., additional, De Jay, N., additional, Ramkissoon, L., additional, Corcoran, A., additional, Jones, D., additional, Sturm, D., additional, Johann, P., additional, Tomita, T., additional, Nagib, M., additional, Bendel, A., additional, Goumnerova, L., additional, Bowers, D. C., additional, Leonard, J. R., additional, Rubin, J. B., additional, Alden, T., additional, DiPatri, A., additional, Browd, S., additional, Leary, S., additional, Jallo, G., additional, Prados, M. D., additional, Banerjee, A., additional, Carret, A.-S., additional, Ellezam, B., additional, Crevier, L., additional, Klekner, A., additional, Bognar, L., additional, Hauser, P., additional, Garami, M., additional, Myseros, J., additional, Dong, Z., additional, Siegel, P. M., additional, Gump, W., additional, Ayyanar, K., additional, Ragheb, J., additional, Krieger, M., additional, Kiehna, E., additional, Robison, N., additional, Harter, D., additional, Gardner, S., additional, Handler, M., additional, Foreman, N., additional, Brahma, B., additional, MacDonald, T., additional, Malkin, H., additional, Chi, S., additional, Manley, P., additional, Bandopadhayay, P., additional, Greenspan, L., additional, Ligon, A., additional, Albrecht, S., additional, Ligon, K. L., additional, Majewski, J., additional, Jabado, N., additional, Cordero, F., additional, Halvorson, K., additional, Taylor, I., additional, Hutt, M., additional, Weingart, M., additional, Price, A., additional, Kantar, M., additional, Onen, S., additional, Kamer, S., additional, Turhan, T., additional, Kitis, O., additional, Ertan, Y., additional, Cetingul, N., additional, Anacak, Y., additional, Akalin, T., additional, Ersahin, Y., additional, Mason, G., additional, Ho, C., additional, Crozier, F., additional, Vezina, G., additional, Packer, R., additional, Hwang, E., additional, Gilheeney, S., additional, Millard, N., additional, DeBraganca, K., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Donzelli, M., additional, Fischer, C., additional, Petriccione, M., additional, Dunkel, I., additional, Afzal, S., additional, Fleming, A., additional, Larouche, V., additional, Zelcer, S., additional, Johnston, D. L., additional, Kostova, M., additional, Mpofu, C., additional, Decarie, J.-C., additional, Strother, D., additional, Lafay-Cousin, L., additional, Eisenstat, D., additional, Fryer, C., additional, Hukin, J., additional, Hsu, M., additional, Lasky, J., additional, Moore, T., additional, Liau, L., additional, Davidson, T., additional, Prins, R., additional, Hassal, T., additional, Baugh, J., additional, Kirkendall, J., additional, Doughman, R., additional, Leach, J., additional, Jones, B., additional, Miles, L., additional, Hargrave, D., additional, Jacques, T., additional, Savage, S., additional, Saunders, D., additional, Wallace, R., additional, Flutter, B., additional, Morgenestern, D., additional, Blanco, E., additional, Howe, K., additional, Lowdell, M., additional, Samuel, E., additional, Michalski, A., additional, Anderson, J., additional, Arakawa, Y., additional, Umeda, K., additional, Watanabe, K.-i., additional, Mizowaki, T., additional, Hiraoka, M., additional, Hiramatsu, H., additional, Adachi, S., additional, Kunieda, T., additional, Takagi, Y., additional, Miyamoto, S., additional, Venneti, S., additional, Santi, M., additional, Felicella, M. M., additional, Sullivan, L. M., additional, Dolgalev, I., additional, Martinez, D., additional, Perry, A., additional, Lewis, P. W., additional, Allis, D. C., additional, Thompson, C. B., additional, and Judkins, A. R., additional
Published: 2014
Full Text: View/download PDF

31. ATYPICAL TERATOID RHABDOID TUMOUR

Author: Bertozzi, A. I., primary, Munzer, C., additional, Fouyssac, F., additional, Andre, N., additional, Boetto, S., additional, Leblond, P., additional, Bourdeaut, F., additional, Dufour, C., additional, Deshpande, R. K., additional, Bhat, K. G., additional, Mahalingam, S., additional, Muscat, A., additional, Cain, J., additional, Ferguson, M., additional, Popovski, D., additional, Algar, E., additional, Rossello, F. J., additional, Jayasekara, S., additional, Watkins, D. N., additional, Hodge, J., additional, Ashley, D., additional, Hishii, M., additional, Saito, M., additional, Arai, H., additional, Han, Z. Y., additional, Richer, W., additional, Lucchesi, C., additional, Freneaux, P., additional, Nicolas, A., additional, Grison, C., additional, Pierron, G., additional, Delattre, O., additional, Epari, S., additional, TS, N., additional, Gupta, T., additional, Chinnaswamy, G., additional, Sastri, J. G., additional, Shetty, P., additional, Moiyadi, A., additional, Jalali, R., additional, Fay-McClymont, T., additional, Johnston, D., additional, Janzen, L., additional, Guger, S., additional, Scheinemann, K., additional, Fleming, A., additional, Fryer, C., additional, Hukin, J., additional, Mabbott, D., additional, Huang, A., additional, Bouffet, E., additional, Lafay-Cousin, L., additional, Kawamura, A., additional, Yamamoto, K., additional, Nagashima, T., additional, Bartelheim, K., additional, Benesch, M., additional, Buchner, J., additional, Gerss, J., additional, Hasselblatt, M., additional, Kortmann, R.-D., additional, Fleischack, G., additional, Quiroga, E., additional, Reinhard, H., additional, Schneppenheim, R., additional, Seeringer, A., additional, Siebert, R., additional, Timmermann, B., additional, Warmuth-Metz, M., additional, Schmid, I., additional, Fruhwald, M. C., additional, Kerl, K., additional, Klingebiel, T., additional, Al-Kofide, A., additional, Khafaga, Y., additional, Al-Hindi, H., additional, Dababo, M., additional, Ul-Haq, A., additional, Anas, M., additional, Barria, M. G., additional, Siddiqui, K., additional, Hassounah, M., additional, Ayas, M., additional, Al-Shail, E., additional, Jeibmann, A., additional, Eikmeier, K., additional, Linge, A., additional, Johann, P., additional, Koos, B., additional, Kool, M., additional, Pfister, S. M., additional, Paulus, W., additional, Schuller, U., additional, Junckerstorff, R., additional, Rosenblum, M. K., additional, Alassiri, A. H., additional, Rossi, S., additional, Gottardo, N., additional, Toledano, H., additional, Viscardi, E., additional, Witkowski, L., additional, Nagel, I., additional, Oyen, F., additional, Foulkes, W. D., additional, Schrey, D., additional, Malietzis, G., additional, Chi, S., additional, Marshall, L., additional, Carceller, F., additional, Moreno, L., additional, Zacharoulis, S., additional, Bhardwaj, R., additional, Chakravadhanula, M., additional, Ozals, V., additional, Hampton, C., additional, Metpally, R., additional, Grillner, P., additional, Asmundsson, J., additional, Gustavsson, B., additional, Holm, S., additional, Johann, P. D., additional, Korshunov, A., additional, Ryzhova, M., additional, Milde, T., additional, Witt, O., additional, Jones, D. T. W., additional, Hovestadt, V., additional, Gajjar, A., additional, Fruhwald, M., additional, Pfister, S., additional, Finetti, M., additional, Pons, A. d. C., additional, Selby, M., additional, Smith, A., additional, Crosier, S., additional, Wood, J., additional, Skalkoyannis, B., additional, Bailey, S., additional, Clifford, S., additional, Williamson, D., additional, Rutkowski, S., additional, Kortmann, R. D., additional, Graf, N., additional, Boos, J., additional, Nysom, K., additional, Moreno, N., additional, Holsten, T., additional, Ahlfeld, J., additional, Mertins, J., additional, Hotfilder, M., additional, Schleicher, S., additional, Handgretinger, R., additional, Meisterernst, M., additional, Schmidt, C., additional, Dittmar, S., additional, Chan, G. C. F., additional, Shing, M. M. K., additional, Yuen, H. L., additional, Li, R. C. H., additional, Ling, S. L., additional, Slavc, I., additional, Peyrl, A., additional, Chocholous, M., additional, Azizi, A., additional, Czech, T., additional, Dieckmann, K., additional, Haberler, C., additional, Leiss, U., additional, Gotti, G., additional, Biassoni, V., additional, Schiavello, E., additional, Spreafico, F., additional, Pecori, E., additional, Gandola, L., additional, Massimino, M., additional, Kornelius, K., additional, Yano, H., additional, Nakayama, N., additional, Ohe, N., additional, Ozeki, M., additional, Kanda, K., additional, Kimura, T., additional, Hori, T., additional, Fukao, T., additional, Iwama, T., additional, Weil, A. G., additional, Diaz, A., additional, Gernsback, J., additional, Bhatia, S., additional, Ragheb, J., additional, Niazi, T., additional, Khatib, Z., additional, Zoghbi, A., additional, Meisterernst, a. M., additional, Birks, D., additional, Griesinger, A., additional, Amani, V., additional, Donson, A., additional, Posner, R., additional, Dunham, C., additional, Kleinschmidt-DeMasters, B. K., additional, Handler, M., additional, Vibhakar, R., additional, Foreman, N., additional, Zhou, L., additional, Catchpoole, D., additional, Kakkar, A., additional, Biswas, A., additional, Suri, V., additional, Sharma, M., additional, Kale, S., additional, Mahapatra, A., additional, Sarkar, C., additional, Torchia, J., additional, Picard, D., additional, Ho, K. C., additional, Khuong-Quang, D.-A., additional, Louterneau, L., additional, Bourgey, M., additional, Chan, T., additional, Golbourn, B., additional, Cousin, L.-L., additional, Taylor, M. D., additional, Dirks, P., additional, Rutka, J. T., additional, Hawkins, C., additional, Majewski, J., additional, Kim, S.-K., additional, Jabado, N., additional, Chang, J. H.-C., additional, Confer, M., additional, Chang, A., additional, Goldman, S., additional, Dunn, M., additional, and Hartsell, W., additional
Published: 2014
Full Text: View/download PDF

32. EPENDYMOMA

Author: Zaghloul, M., primary, Elbeltagy, M., additional, Mousa, A., additional, Eldebawy, E., additional, Amin, A., additional, Pavelka, Z., additional, Vranova, V., additional, Valaskova, I., additional, Tomasikova, L., additional, Oltova, A., additional, Ventruba, J., additional, Mackerle, Z., additional, Kren, L., additional, Skotakova, J., additional, Zitterbart, K., additional, Sterba, J., additional, Milde, T., additional, Kleber, S., additional, Korshunov, A., additional, Witt, H., additional, Hielscher, T., additional, Koch, P., additional, Koch, H.-G., additional, Jugold, M., additional, Deubzer, H. E., additional, Oehme, I., additional, Lodrini, M., additional, Grone, H.-J., additional, Benner, A., additional, Brustle, O., additional, Gilbertson, R. J., additional, von Deimling, A., additional, Kulozik, A. E., additional, Pfister, S. M., additional, Ana, M.-V., additional, Witt, O., additional, Kool, M., additional, Mack, S. C., additional, Taylor, M. D., additional, Fouyssac, F., additional, Schmitt, E., additional, Mansuy, L., additional, Marchal, J.-C., additional, Coffinet, L., additional, Bernier, V., additional, Chastagner, P., additional, Sperl, D., additional, Zacharoulis, S., additional, Massimino, M., additional, Schiavello, E., additional, Pizer, B., additional, Piette, C., additional, Kitanovski, L., additional, von Hoff, K., additional, Quehenberger, F., additional, Rutkowski, S., additional, Benesch, M., additional, Tzaridis, T.-D., additional, Bender, S., additional, Pfaff, E., additional, Barbus, S., additional, Bageritz, J., additional, Jones, D.-T.-W., additional, Kulozik, A., additional, Lichter, P., additional, Pfister, S.-M., additional, Song, S.-H., additional, Kang, C.-W., additional, Kim, S.-H., additional, Bandopadhayay, P., additional, Ullrich, N., additional, Goumnerova, L., additional, Scott, R. M., additional, Silvera, V. M., additional, Ligon, K. L., additional, Marcus, K. J., additional, Robison, N., additional, Manley, P. E., additional, Chi, S., additional, Kieran, M. W., additional, Biassoni, V., additional, Pierani, P., additional, Cesaro, S., additional, Maura, M., additional, Mack, S., additional, Jager, N., additional, Jones, D. T. W., additional, Stutz, A., additional, Northcott, P. A., additional, Fults, D. W., additional, Gupta, N., additional, Karajannis, M., additional, Rutka, J. T., additional, Korbel, J., additional, de Rezende, A. C. P., additional, Chen, M. J., additional, da Silva, N. S., additional, Cappellano, A., additional, Cavalheiro, S., additional, Weltman, E., additional, Currle, S., additional, Thiruvenkatam, R., additional, Murugesan, M., additional, Kranenburg, T., additional, Phoenix, T., additional, Gupta, K., additional, Gilbertson, R., additional, Rogers, H., additional, Kilday, J.-P., additional, Mayne, C., additional, Ward, J., additional, Adamowicz-Brice, M., additional, Schwalbe, E., additional, Clifford, S., additional, Coyle, B., additional, Grundy, R., additional, Mitra, B., additional, Domerg, C., additional, Andreiuolo, F., additional, Osteso-Ibanez, T., additional, Mauguen, A., additional, Varlet, P., additional, Le Deley, M.-C., additional, Lowe, J., additional, Ellison, D. W., additional, Grill, J., additional, Grundy, R. G., additional, Fleischhack, G., additional, Pajtler, K., additional, Zimmermann, M., additional, Warmuth-Metz, M., additional, Kortmann, R.-D., additional, Pietsch, T., additional, Faldum, A., additional, Bode, U., additional, Gandola, L., additional, Pecori, E., additional, Scarzello, G., additional, Barra, S., additional, Mascarin, M., additional, Scoccianti, S., additional, Mussano, A., additional, Garre, M. L., additional, Jacopo, S., additional, Viscardi, E., additional, Balter, R., additional, Bertin, D., additional, Giangaspero, F., additional, Pearlman, M., additional, Khatua, S., additional, Van Meter, T., additional, Koul, D., additional, Yung, A., additional, Paulino, A., additional, Su, J., additional, Dauser, R., additional, Whitehead, W., additional, Teh, B., additional, Chintagumpala, M., additional, Perek, D., additional, Drogosiewicz, M., additional, Filipek, I., additional, Polnik, M. P., additional, Baginska, B. D., additional, Wachowiak, J., additional, Kazmierczak, B., additional, Sobol, G., additional, Musiol, K., additional, Kowalczyk, J., additional, Slusarz, H. W., additional, Peregud-Pogorzelski, J., additional, Grajkowska, W., additional, Roszkowski, M., additional, Teo, W.-Y., additional, Okcu, F., additional, Mahajan, A., additional, Adesina, A., additional, Jea, A., additional, Bollo, R., additional, Paulino, A. C., additional, Velez-Char, N., additional, Doerner, E., additional, Muehlen, A. z., additional, Vladimirova, V., additional, Kortmann, R., additional, Friedrich, C., additional, von Bueren, A. O., additional, Barszczyk, M., additional, Buczkowicz, P., additional, Morrison, A., additional, Tabori, U., additional, Hawkins, C., additional, Krajewski, K., additional, Kammler, G., additional, von Bueren, A., additional, Krauss, J., additional, Ferreira, C., additional, Dieffenbach, G., additional, Barbosa, C., additional, Cuny, P., additional, Piccinin, E., additional, Brenca, M., additional, Lorenzetto, E., additional, Sardi, I., additional, Genitori, L., additional, Pollo, B., additional, Maestro, R., additional, Modena, P., additional, MacDonald, S., additional, Ebb, D., additional, Lavally, B., additional, Yeap, B., additional, Marcus, K., additional, Tarbell, N., additional, Yock, T., additional, Schittone, S., additional, Donson, A., additional, Birks, D., additional, Amani, V., additional, Griesinger, A., additional, Handler, M., additional, Madey, M., additional, Merchant, T., additional, Foreman, N., additional, Hukin, J., additional, Ailon, T., additional, Dunham, C., additional, Carret, A.-S., additional, McNeely, P. D., additional, Zelcer, S., additional, Wilson, B., additional, Lafay-Cousin, L., additional, Johnston, D., additional, Eisenstat, D., additional, Silva, M., additional, Jabado, N., additional, Yip, S., additional, Goddard, K., additional, Fryer, C., additional, Hendson, G., additional, Dunn, S., additional, Singhal, A., additional, Lassen-Ramshad, Y., additional, Vestergaard, A., additional, Seiersen, K., additional, Schultz, H. P., additional, Hoeyer, M., additional, Petersen, J. B., additional, Moreno, L., additional, Popov, S., additional, Jury, A., additional, Al Sarraj, S., additional, Jones, C., additional, Bowers, D., additional, Gargan, L., additional, Horton, C. J., additional, Rakheja, D., additional, Margraf, L., additional, Yeung, J., additional, Hamilton, R., additional, Okada, H., additional, Jakacki, R., additional, Pollack, I., additional, Fleming, A., additional, Saint-Martin, C., additional, Freeman, C., additional, Albrecht, S., additional, and Montes, J.-L., additional
Published: 2012
Full Text: View/download PDF

33. QUALITY OF LIFE/AFTERCARE

Author: Rednam, S., primary, Scheurer, M., additional, Adesina, A., additional, Lau, C., additional, Okcu, M., additional, Deatrick, J., additional, Ogle, S., additional, Fisher, M., additional, Barakat, L., additional, Hardie, T., additional, Li, Y., additional, Ginsberg, J., additional, Ben-Arush, M., additional, Krivoy, E., additional, Rosenkranz, R., additional, Peretz-Nahum, M., additional, Brown, R. J., additional, Love, J., additional, Warburton, D., additional, McBride, W. H., additional, Bluml, S., additional, Mueller, S., additional, Sear, K., additional, Hills, N., additional, Chettout, N., additional, Afghani, S., additional, Lew, L., additional, Tolentino, E., additional, Haas-Kogan, D., additional, Fullerton, H., additional, Reddick, W., additional, Palmer, S., additional, Glass, J., additional, Ogg, R., additional, Gajjar, A., additional, Omar, A., additional, Perkins, S., additional, Shinohara, E., additional, Spoljaric, D., additional, Isenberg, J., additional, Whittington, M., additional, Hauff, M., additional, King, A., additional, Litzelman, K., additional, Barker, E., additional, Catrine, K., additional, Puccetti, D., additional, Possin, P., additional, Witt, W., additional, Mallucci, C., additional, Kumar, R., additional, Pizer, B., additional, Williams, D., additional, Pettorini, B., additional, Piscione, J., additional, Bouffet, E., additional, Shams, I., additional, Kulkarni, A., additional, Remes, T., additional, Harila-Saari, A., additional, Suo-Palosaari, M., additional, Arikoski, P., additional, Riikonen, P., additional, Sutela, A., additional, Koskenkorva, P., additional, Ojaniemi, M., additional, Rantala, H., additional, Campen, C. J., additional, Ashby, D., additional, Fisher, P. G., additional, Monje, M., additional, Kulkarni, A. V., additional, Nakamura, H., additional, Makino, K., additional, Yano, S., additional, Kuratsu, J.-i., additional, Jadrijevic-Cvrlje, F., additional, Batinica, M., additional, Toledano, H., additional, Hoffman, T., additional, Ezer-Cohen, Y., additional, Michowiz, S., additional, Yaniv, I., additional, Cohen, I. J., additional, Adler, I., additional, Mindel, S., additional, Gopalakrishnamoorthy, M., additional, Saunders, D., additional, Gaze, M., additional, Spoudeas, H., additional, Kieffer, V., additional, Dellatolas, G., additional, Chevignard, M., additional, Puget, S., additional, Dhermain, F., additional, Grill, J., additional, Dufour, C., additional, Muir, R., additional, Hunter, A., additional, Latchman, A., additional, de Camargo, O., additional, Scheinemann, K., additional, Dhir, N., additional, Zaky, W., additional, Zomorodian, T., additional, Wong, K., additional, Dhall, G., additional, Macy, M., additional, Lauro, C., additional, Zeitler, P., additional, Foreman, N., additional, Liu, A., additional, Chocholous, M., additional, Dodier, P., additional, Peyrl, A., additional, Dieckmann, K., additional, Hausler, G., additional, Slavc, I., additional, Avula, S., additional, Garlick, D., additional, Armstrong, G., additional, Kawashima, T., additional, Leisenring, W., additional, Stovall, M., additional, Sklar, C., additional, Robison, L., additional, Samaan, C., additional, Duckworth, J., additional, Greenberg-Kushnir, N., additional, Freedman, S., additional, Eshel, R., additional, Zverling, N., additional, Elhasid, R., additional, Dvir, R., additional, Yalon, M., additional, Constantini, S., additional, Wilne, S., additional, Liu, J.-F., additional, Trusler, J., additional, Lundsell, S., additional, Kennedy, C., additional, Clough, L., additional, Dickson, N., additional, Lakhanpaul, M., additional, Baker, M., additional, Dudley, J., additional, Grundy, R., additional, Walker, D., additional, von Hoff, K., additional, Herzog, N., additional, Ottensmeier, H., additional, Grabow, D., additional, Gerber, N. U., additional, Friedrich, C., additional, von Bueren, A. O., additional, Resch, A., additional, Kortmann, R. D., additional, Kaatsch, P., additional, Doerr, H. G., additional, Rutkowski, S., additional, del Bufalo, F., additional, Mastronuzzi, A., additional, Serra, A., additional, de Sio, L., additional, Locatelli, F., additional, Biassoni, V., additional, Leonardi, M., additional, Ajovalasit, D., additional, Riva, D., additional, Vago, C., additional, Usilla, A., additional, Fidani, P., additional, Schiavello, E., additional, Gariboldi, F., additional, Massimino, M., additional, Lober, R., additional, Perrault, S., additional, Partap, S., additional, Edwards, M., additional, Fisher, P., additional, Yeom, K., additional, Salgado, D., additional, Nunes, S., additional, Vinhais, S., additional, Wells, E. M., additional, Seidel, K., additional, Ullrich, N. J., additional, Diller, L., additional, Krull, K. R., additional, Neglia, J., additional, Robison, L. L., additional, Whelan, K., additional, Russell, C. E., additional, Brownstone, D., additional, Kaise, C., additional, Bull, K., additional, Culliford, D., additional, Calaminus, G., additional, Bertin, D., additional, Vallero, S., additional, Romano, E., additional, Basso, M. E., additional, Biasin, E., additional, Fagioli, F., additional, Ziara, K., additional, L'Hotta, A., additional, Williams, A., additional, Thede, R., additional, Moore, K., additional, James, A., additional, Bjorn, E., additional, Franzen, P., additional, Haag, A., additional, Lax, A.-K., additional, Moreno, I., additional, Obeid, J., additional, Timmons, B. W., additional, Iwata, W., additional, Wagner, S., additional, Lai, J.-S., additional, Waddell, K., additional, VanLeeuwen, S., additional, Newmark, M., additional, Noonan, J., additional, O'Connell, K., additional, Urban, M., additional, Yount, S., additional, Goldman, S., additional, Igoe, D., additional, Cunningham, T., additional, Orfus, M., additional, Mabbott, D., additional, Liptak, C., additional, Manley, P., additional, Recklitis, C., additional, Zhang, P., additional, Shaikh, F., additional, Narang, I., additional, Matsumoto, K., additional, Yamasaki, K., additional, Okada, K., additional, Fujisaki, H., additional, Osugi, Y., additional, Hara, J., additional, Phipps, K., additional, Gumley, D., additional, Jacques, T., additional, Hargrave, D., additional, Michalski, A., additional, Chordas, C., additional, Chi, S., additional, Robison, N., additional, Bandopadhayay, P., additional, Marcus, K., additional, Zimmerman, M. A., additional, Goumnerova, L., additional, Kieran, M., additional, Brand, S., additional, Brinkman, T., additional, Delaney, B., additional, Diver, T., additional, Rey, C., additional, Madden, J. R., additional, Hemenway, M. S., additional, Dorneman, L., additional, Stiller, D., additional, Liu, A. K., additional, Foreman, N. K., additional, Vibhakar, R., additional, Mitchell, M., additional, Hemenway, M., additional, Madden, J., additional, Ryan, M., additional, O'Kane, R., additional, Picton, S., additional, Kenny, T., additional, Stiller, C., additional, Chumas, P., additional, Bendel, A., additional, Patterson, R., additional, Barrera, M., additional, Schulte, F., additional, Bartels, U., additional, Janzen, L., additional, Johnston, D., additional, Cataudella, D., additional, Chung, J., additional, Sung, L., additional, Hancock, K., additional, Hukin, J., additional, Zelcer, S., additional, Brandon, S., additional, Montour-Proulx, I., additional, Strother, D., additional, Cooksey, R., additional, Bowers, D., additional, Gargan, L., additional, Gode, A., additional, Klesse, L., additional, Oden, J., additional, Vega, G., additional, Sala, F., additional, Nuzzi, D., additional, Mulino, M., additional, Masotto, B., additional, Mazza, C., additional, Bricolo, A., additional, Gerosa, M., additional, Tong, M., additional, Laughlin, S., additional, Mackie, S., additional, Taylor, L., additional, Sharpe, G., additional, Al-Salihi, O., additional, and Nicolin, G., additional
Published: 2012
Full Text: View/download PDF

34. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Author: Zaghloul, M., primary, Ahmed, S., additional, Eldebaway, E., additional, Mousa, A., additional, Amin, A., additional, Elkhateeb, N., additional, Sabry, M., additional, Ogiwara, H., additional, Morota, N., additional, Sufit, A., additional, Donson, A., additional, Birks, D., additional, Patel, P., additional, Foreman, N., additional, Handler, M., additional, Massimino, M., additional, Biassoni, V., additional, Gandola, L., additional, Schiavello, E., additional, Pecori, E., additional, Potepan, P., additional, Bach, F., additional, Janssens, G. O., additional, Jansen, M. H., additional, Lauwers, S. J., additional, Nowak, P. J., additional, Oldenburger, F. R., additional, Bouffet, E., additional, Saran, F., additional, van Ulzen, K. K., additional, van Lindert, E. J., additional, Schieving, J. H., additional, Boterberg, T., additional, Kaspers, G. J., additional, Span, P. N., additional, Kaanders, J. H., additional, Gidding, C. E., additional, Hargrave, D., additional, Bailey, S., additional, Howman, A., additional, Pizer, B., additional, Harris, D., additional, Jones, D., additional, Kearns, P., additional, Picton, S., additional, Wheatley, K., additional, Gibson, M., additional, Glaser, A., additional, Connolly, D., additional, Kawamura, A., additional, Nagashima, T., additional, Yamamoto, K., additional, Sakata, J., additional, Lober, R., additional, Freret, M., additional, Fisher, P., additional, Edwards, M., additional, Yeom, K., additional, Monje, M., additional, Jansen, M., additional, Aliaga, E. S., additional, Van Der Hoeven, E., additional, Van Vuurden, D., additional, Heymans, M., additional, Gidding, C., additional, De Bont, E., additional, Reddingius, R., additional, Peeters-Scholte, C., additional, van Meeteren, A. S., additional, Gooskens, R., additional, Granzen, B., additional, Paardekoper, G., additional, Janssens, G., additional, Noske, D., additional, Barkhof, F., additional, Vandertop, W. P., additional, Kaspers, G., additional, Saratsis, A., additional, Yadavilli, S., additional, Nazarian, J., additional, Mitra, S., additional, Mallick, S., additional, Kim, J., additional, Beachy, P., additional, Nobre, L., additional, Vasconcelos, F., additional, Lima, F., additional, Mattos, D., additional, Kuiven, N., additional, Lima, G., additional, Silveira, J., additional, Sevilha, M., additional, Lima, M. A., additional, Ferman, S., additional, Leblond, P., additional, Lansiaux, A., additional, Rialland, X., additional, Gentet, J.-C., additional, Geoerger, B., additional, Frappaz, D., additional, Aerts, I., additional, Bernier-Chastagner, V., additional, Shah, R., additional, Zaky, W., additional, Grimm, J., additional, Bluml, S., additional, Wong, K., additional, Dhall, G., additional, Caretti, V., additional, Schellen, P., additional, Lagerweij, T., additional, Bugiani, M., additional, Navis, A., additional, Wesseling, P., additional, Noske, D. P., additional, Wurdinger, T., additional, Lee, H., additional, Ziegler, D., additional, Schroeder, K., additional, Huang, E., additional, Berlow, N., additional, Patel, R., additional, Becher, O., additional, Taylor, I., additional, Mao, X.-g., additional, Hutt, M., additional, Weingart, M., additional, Kahlert, U., additional, Maciacyk, J., additional, Nikkhah, G., additional, Eberhart, C., additional, Raabe, E., additional, Barton, K., additional, Misuraca, K., additional, Zhou, Z., additional, Rotman, L., additional, Ho, S., additional, Souweidane, M., additional, Lim, K. J., additional, Warren, K., additional, Chang, H., additional, Lightner, D., additional, Haque, S., additional, Khakoo, Y., additional, Dunkel, I., additional, Gilheeney, S., additional, Kramer, K., additional, Lyden, D., additional, Wolden, S., additional, Greenfield, J., additional, De Braganca, K., additional, Ting-Rong, H., additional, Muh-Li, L., additional, Kai-Ping, C., additional, Tai-Tong, W., additional, Hsin-Hung, C., additional, Kebudi, R., additional, Cakir, F. B., additional, Agaoglu, F. Y., additional, Gorgun, O., additional, Dizdar, Y., additional, Ayan, I., additional, Darendeliler, E., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Kodet, R., additional, Kyncl, M., additional, Tichy, M., additional, Stary, J., additional, Sumerauer, D., additional, Minturn, J., additional, Shu, H.-K., additional, Fisher, M., additional, Patti, R., additional, Janss, A., additional, Allen, J., additional, Phillips, P., additional, Belasco, J., additional, Taylor, K., additional, Baudis, M., additional, von Beuren, A., additional, Fouladi, M., additional, and Jones, C., additional
Published: 2012
Full Text: View/download PDF

35. 4125 POSTER Nimotuzumab and Vinorelbine Concomitantly to Radiation and as Maintenance for Diffuse Pontine Glioma in Childhood – Promising Results on a Series of 13 Patients

Author: Massimino, M., primary, Biassoni, V., additional, Gandola, L., additional, Schiavello, E., additional, Pecori, E., additional, Potepan, P., additional, and Bach, F., additional
Published: 2011
Full Text: View/download PDF

36. Nimotuzumab and vinorelbine concomitantly to radiation and as maintenance for diffuse pontine glioma in childhood: Results from a series of 12 patients.

Author: Massimino, M., primary, Biassoni, V., additional, Gandola, L., additional, Schiavello, E., additional, Pecori, E., additional, and Bach, F., additional
Published: 2011
Full Text: View/download PDF

37. Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results.

Author: Devizzi, L., primary, Guidetti, A., additional, Carlo-Stella, C., additional, Tarella, C., additional, Seregni, E., additional, Magni, M., additional, Di Nicola, M. A., additional, Schiavello, E., additional, Matteucci, P., additional, Viviani, S., additional, Bombardieri, E., additional, and Gianni, A. M., additional
Published: 2011
Full Text: View/download PDF

38. Pediatrics Clinical Research

Author: Wrede, B., primary, Peters, O., additional, Kordes, U., additional, Kutluk, T., additional, Hasselblatt, M., additional, Rytting, M., additional, Rutkowski, S., additional, Mahajan, A., additional, Pietsch, T., additional, Thall, P., additional, Wolff, J. E., additional, Pfister, S., additional, Bingham, R., additional, Vats, T., additional, Rokes, C., additional, Brown, R., additional, Creach, K. M., additional, Rubin, J. B., additional, Leonard, J. R., additional, Limbrick, D. D., additional, Smyth, M. D., additional, Dacey, R. G., additional, Rich, K. M., additional, Dowling, J. L., additional, Linette, G. P., additional, King, A. A., additional, Michalski, J. M., additional, Simpson, J. R., additional, Park, T. S., additional, Perry, A., additional, Mansur, D. B., additional, Gururangan, S., additional, Panandikar, A. P., additional, Broniscer, A., additional, Huang, A., additional, Kellie, S., additional, Ellison, D., additional, Gajjar, A., additional, Aguilera, D., additional, Goldman, S., additional, Tomita, T., additional, Fangusaro, J., additional, Poussaint, T. Y., additional, Onar, A., additional, Gilbertson, R., additional, Packer, R., additional, McClendon, R., additional, Friedman, H., additional, Boyett, J., additional, Baker, J. N., additional, Tagen, M., additional, Onar-Thomas, A., additional, Gilbertson, R. J., additional, Davidoff, A. M., additional, Pai-Panandiker, A., additional, Leung, W., additional, Chin, T. K., additional, Stewart, C. F., additional, Kocak, M., additional, Rowland, C., additional, Merchant, T. E., additional, Kaste, S., additional, Allen, J., additional, Donahue, B., additional, Mathew, J., additional, Kretschmar, C., additional, Pollack, I., additional, Jakacki, R., additional, Massimino, M., additional, Biassoni, V., additional, Gandola, L., additional, Ferroli, P., additional, Bongarzone, I., additional, Spreafico, F., additional, Pecori, E., additional, Schiavello, E., additional, Modena, P., additional, Bach, F., additional, Potepan, P., additional, Slavc, I., additional, Peyrl, A., additional, Czech, T., additional, Haberler, C., additional, Dieckmann, K., additional, Brown, R. J., additional, Dhall, G., additional, Marachelian, A., additional, Gozali, A., additional, Butturini, A., additional, Gilles, F., additional, Thompson, S. J., additional, Gardner, S., additional, Finlay, J. L., additional, Eisenstat, D. D., additional, and Evans, A., additional
Published: 2010
Full Text: View/download PDF

39. Outcome and long-term complications

Author: Biassoni, V., Schiavello, E., Gandola, L., Seregni, E., Indini, A., Spreafico, F., and Maura Massimino

40. HYPOFRACTIONATED RADIOTHERAPY (RT) BOOST FOR CHILDREN WITH EPENDYMOMA AND A MEASURABLE RESIDUE AFTER SURGERY: THE ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY AND ONCOLOGY (AIEOP) EXPERIENCE

Author: Massimino, M., Giangaspero, F., Pignoli, E., Schiavello, E., Biassoni, V., Meroni, S., Sardi, I., Garre, M. L., Mussano, A., Diletto, B., Scoccianti, S., Maurizio Mascarin, Barra, S., Scarzello, G., Pecori, E., and Gandola, L.

41. The youth project at the Istituto Nazionale Tumori in Milan

Author: Ferrari, A., Clerici, C. A., Casanova, M., Luksch, R., Terenziani, M., Filippo Spreafico, Polastri, D., Meazza, C., Veneroni, L., Catania, S., Schiavello, E., Biassoni, V., Podda, M., and Massimino, M.
Subjects: 03 medical and health sciences, Cancer Research, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, General Medicine, 030218 nuclear medicine & medical imaging
Abstract: The paper describes the key issues of the Youth Project launched in 2011 at the pediatric oncology unit of the Istituto Nazionale Tumori in Milan dedicated to adolescents (over 15 years old) and young adults (up to 25 years old) with solid tumors. The Youth Project was developed within the pediatric oncology unit in the conviction that adolescent patients may benefit from the multidisciplinary team typical of the pediatric oncology setting, as well as the expertise in treating pediatric-type malignancies and enrolling patients in clinical trials. The project was an offshoot of existing activities, making no major changes to the hospital's organization and posing no major demands on the institution's administration and board. Patients are managed by the pediatric oncology staff, but they have access to particular services (e.g., regarding their psychosocial support, fertility preserving measures, access to care after completing therapy); dedicated, adequately equipped multifunctional rooms have been provided. The location of the pediatric unit within a cancer referral center and the cooperation with divisions dedicated to adults have played an important role in the project's creation.

42. Neuroblastoma in patients over 12 years old: A 20-year experience at the Istituto Nazionale Tumori of Milan

Author: Podda, M. G., Luksch, R., Polastri, D., Gandola, L., Piva, L., Collini, P., Cefalo, G., Monica Terenziani, Ferrari, A., Casanova, M., Spreafico, F., Meazza, C., Castellani, M. R., Catania, S., Schiavello, E., Marchianò, A., and Massimino, M.
Subjects: Adult, Male, Cancer Research, Adolescent, General Medicine, Middle Aged, Thoracic Neoplasms, 030218 nuclear medicine & medical imaging, Neuroblastoma, Young Adult, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Oncology, Chemotherapy, Adjuvant, Abdominal Neoplasms, 030220 oncology & carcinogenesis, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Radiotherapy, Adjuvant, Dose Fractionation, Radiation, Aged, Neoplasm Staging, Retrospective Studies
Abstract: Aims and background Neuroblastoma is the most common solid extracranial tumor in children. The median age of onset is 2 years, with more than 95% of patients younger than 10 years at diagnosis. As neuroblastoma is rare in adolescents and exceedingly rare in adults, few series are reported in the literature. In the present study, we analyzed the outcomes and clinical characteristics of a mono-institutional series. Methods We describe 27 consecutive patients over 12 years of age (range, 12–69) with previously untreated neuroblastoma treated at our Institution between 1982 and 2001. Results Overall survival at 5 and 10 years was 40% and 20%, respectively, and progression-free survival at 5 and 10 years was 18%. In the present series, there was a long interval between the onset of signs/symptoms and diagnosis, and between recurrence/progression and death. None had MYCN amplification. Conclusions The passive course of the disease in most of our patients did not reflect a more favorable outcome compared with younger patients, thus suggesting a possible genetically different subset of neuroblastoma in older patients. Free full text available at www.tumorionline.it

43. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Author: Massimino M, Miceli R, Giangaspero F, Boschetti L, Modena P, Antonelli M, Ferroli P, Bertin D, Pecori E, Valentini L, Biassoni V, Ml, Garrè, Schiavello E, Sardi I, Cama A, Viscardi E, Scarzello G, Scoccianti S, Mascarin M, and Quaglietta L

44. Cervicomedullary Gliomas in Pediatric Age: A Systematic Review of the Literature and Tertiary Care Center Experience

Author: Andrea Trezza, Camilla de Laurentis, Veronica Biassoni, Giorgio G. Carrabba, Elisabetta Schiavello, Francesco Canonico, Paolo Remida, Alessandra Moretto, Maura Massimino, Carlo Giussani, Trezza, A, de Laurentis, C, Biassoni, V, Carrabba, G, Schiavello, E, Canonico, F, Remida, P, Moretto, A, Massimino, M, and Giussani, C
Subjects: Cervicomedullary glioma, Cervicomedullary tumor, Pediatric brain tumor, Pediatrics, Perinatology and Child Health, Surgery, Neurology (clinical), General Medicine
Abstract: Introduction: Cervicomedullary gliomas (CMGs) are usually low-grade tumors often found in the pediatric age. Histological findings, treatments, and classification have been much the same for 40 years, although histological and molecular classifications have largely been developed for other pediatric CNS tumors. The management and treatment of pediatric CMG are still conducted by many authors according to their anatomical location and characteristics, independently from histology. Methods: We conducted a literature review in PubMed (Medline) to identify relevant contributions about pediatric CMG published until December 31, 2021. We also analyzed a series of 10 patients with CMG treated from 2006 to 2021 at IRCCS Istituto Nazionale dei Tumori. The aim of the present review was to see whether and how the diagnosis, treatment, and classification of CMGs in children have developed over time, especially in the context of molecular advancements, and to analyze our single-center experience in the last 15 years. Results: Thirty articles have been included in the review. Articles have been divided into two historical periods (1981–2000 and 2001–2021) and data from different series were analyzed to see how much the management and treatment of pediatric CMG have changed during years. Analysis of our series of 10 patients affected by CMG was also performed to compare it with the literature. Discussion: Management and classification of CMG in children have not dramatically changed during years. However, new insight from molecular diagnostics and target therapies and the development of radiological, neurophysiological, and radiotherapy techniques have updated treatment modalities in the last 20 years. Treatment modalities and their innovations have been reviewed and discussed. Further studies are needed to standardize and customize treatment protocols for these tumors.
Published: 2022
Full Text: View/download PDF

45. Retrospective analysis of the clinical and radiological features of 94 consecutive DIPGs patients to investigate the factors determining the development of hydrocephalus and its impact on clinical status and survival

Author: Carlo Giussani, Maura Massimino, Andrea Trezza, Giorgio Carrabba, Lelio Guida, Veronica Biassoni, Erik P. Sganzerla, Elisabetta Schiavello, Giussani, C, Guida, L, Biassoni, V, Schiavello, E, Carrabba, G, Trezza, A, Sganzerla, E, and Massimino, M
Subjects: Diffuse intrinsic pontine glioma, Pediatrics, medicine.medical_specialty, Disease, Ventriculostomy, 03 medical and health sciences, 0302 clinical medicine, Glutamates, medicine, Retrospective analysis, Humans, Child, Retrospective Studies, Third Ventricle, Hydrocephalu, business.industry, Endoscopic third ventriculostomy, Infant, Retrospective cohort study, General Medicine, Ventriculo peritoneal shunt, medicine.disease, Hydrocephalus, Treatment Outcome, 030220 oncology & carcinogenesis, Radiological weapon, Neuroendoscopy, Pediatrics, Perinatology and Child Health, Cohort, Neurology (clinical), Neurosurgery, business, 030217 neurology & neurosurgery
Abstract: Purpose: There is no consensus in the literature about the impact of hydrocephalus on clinical course and overall survival of diffuse intrinsic pontine gliomas (DIPG) patients as well as about its specific treatment. Authors reviewed a series of DIPG patients to investigate factors related to the onset of hydrocephalus, its treatment, and its impact on clinical course and prognosis. Methods: A retrospective observational study was performed enrolling pediatric patients affected by DIPG from 2008 to 2018. Clinical and radiological charts were reviewed to find patients’ demographic, pathologic and radiologic features in hydrocephalic and non-hydrocephalic patients. In the hydrocephalus cohort, treatment strategy and its effectiveness and complications were analyzed. Results: Ninety-four pediatric patients were enrolled in the study. Patients who developed hydrocephalus showed significantly lesser maximum axial tumor areas than patients without hydrocephalus (respectively 6.5cm2 vs 16.45cm2, p< 0.005). Hydrocephalus developed in 33 patients (35%) with an onset interval of 5.24 ± 1.21months (range 3.2–7.3). The majority of hydrocephalic patients (28 cases, 90%) were treated by ventriculoperitoneal shunt, the remaining 3 patients being treated by endoscopic third ventriculostomy. Mean overall survival was 16.6months ± 20months without significative difference between the groups. Conclusion: The onset of hydrocephalus occurs in the first moths of the disease story and found a negative correlation with tumor maximal axial diameter. Early treatment of hydrocephalus presents a very low complications rate with satisfying clinical outcome, as it allows the patients to continue the neurooncological therapies being a part of the treatment armamentarium instead of a palliative solution.
Published: 2020
Full Text: View/download PDF

46. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

Author: Didier Frappaz, Marie Pierre Sunyach, Roberto Stefini, Manila Antonelli, Carlo Giussani, Elisabetta Schiavello, Roberto Luksch, Monica Terenziani, Alice Bonneville-Levard, Nadia Puma, Carlo Morosi, Luna Boschetti, Lorenza Gandola, Michela Casanova, Luca Bergamaschi, Carmine Mottolese, Barbara Diletto, Anna Garegnani, Emilia Pecori, Giuseppina Calareso, Cristina Meazza, Francesca R. Buttarelli, Federica Pallotti, Giorgio Carrabba, Andrea Ferrari, Veronica Biassoni, Marta Podda, David Meyronet, Stefano Chiaravalli, Filippo Spreafico, Felice Giangaspero, Maura Massimino, Francesco Barretta, Massimino, M, Sunyach, M, Barretta, F, Gandola, L, Garegnani, A, Pecori, E, Spreafico, F, Bonneville-Levard, A, Meyronet, D, Mottolese, C, Boschetti, L, Biassoni, V, Schiavello, E, Giussani, C, Carrabba, G, Diletto, B, Pallotti, F, Stefini, R, Ferrari, A, Terenziani, M, Casanova, M, Luksch, R, Meazza, C, Podda, M, Chiaravalli, S, Puma, N, Bergamaschi, L, Morosi, C, Calareso, G, Giangaspero, F, Antonelli, M, Buttarelli, F, and Frappaz, D
Subjects: Adult, Male, Cancer Research, medicine.medical_specialty, Adult Medulloblastoma, Neurology, Adolescent, medicine.medical_treatment, chemotherapy, Craniospinal Irradiation, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Side-effect, Standard Risk, medicine, Humans, Cerebellar Neoplasms, Retrospective Studies, Medulloblastoma, Chemotherapy, Adult patients, business.industry, adult medulloblastoma, Dose-Response Relationship, Radiation, Middle Aged, Reduced dose, medicine.disease, Prognosis, craniospinal irradiation, side-effects, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Feasibility Studies, Female, Neurology (clinical), Radiology, business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract: Introduction: Medulloblastoma is the most common malignant brain tumor in children, but accounts for only 1% of brain cancers in adults. For standard-risk pediatric medulloblastoma, current therapy includes craniospinal irradiation (CSI) at reduced doses (23.4Gy) associated with chemotherapy. Whereas most same-stage adult patients are still given CSI at 36Gy, with or without chemotherapy, we report here on our use of reduced-dose CSI associated with chemotherapy for older patients. Methods: We gathered non-metastatic patients over 18years old (median age 28years, range 18–48) with minimal or no residual disease after surgery, no negative histological subtypes, treated between 1996–2018 at the Centre Léon Bérard (Lyon) and the INT (Milano). A series of 54 children with similar tumors treated in Milano was used for comparison. Results: Forty-four adults were considered (median follow-up 101months): 36 had 23.4Gy of CSI, and 8 had 30.6Gy, plus a boost to the posterior fossa/tumor bed; 43 had chemotherapy as all 54 children, who had a median 83-month follow-up. The PFS and OS were 82.2 ± 6.1% and 89 ± 5.2% at 5 years, and 78.5 ± 6.9% and 75.2 ± 7.8% at ten, not significantly different from those of the children. CSI doses higher than 23.4Gy did not influence PFS. Female adult patients tended to have a better outcome than males. Conclusion: The results obtained in our combined series are comparable with, or even better than those obtained after high CSI doses, underscoring the need to reconsider this treatment in adults.
Published: 2020

47. Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up

Author: Manila Antonelli, Luisa Chiapparini, Carlo Giussani, Felice Giangaspero, Lucia Quaglietta, Lorenzo Genitori, Lorenza Gandola, Geraldina Poggi, Francesco Barretta, Paolo Ferroli, Maurizio Mascarin, Giuseppe Cinalli, Angela Mastronuzzi, P Bertolini, Antonio Ruggiero, Paola Peretta, Alessandra Erbetta, Daniele Bertin, Iacopo Sardi, Rita Balter, Veronica Biassoni, Maura Massimino, Elisabetta Schiavello, Emilia Pecori, Giovanni Scarzello, Francesca R. Buttarelli, Anna Mussano, Assunta Tornesello, Milena La Spina, Luna Boschetti, Massimo Caldarelli, Elisabetta Viscardi, Carlo Efisio Marras, Salvina Barra, Maria Luisa Garrè, Piergiorgio Modena, Massimino, M, Barretta, F, Modena, P, Giangaspero, F, Chiapparini, L, Erbetta, A, Boschetti, L, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Viscardi, E, Scarzello, G, Mascarin, M, Quaglietta, L, Cinalli, G, Genitori, L, Peretta, P, Mussano, A, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Tornesello, A, La Spina, M, Buttarelli, F, Ruggiero, A, Caldarelli, M, Poggi, G, and Gandola, L
Subjects: Ependymoma, Male, Cancer Research, Pediatrics, medicine.medical_specialty, Adolescent, re-irradiation, 03 medical and health sciences, 0302 clinical medicine, Clinical Protocols, childhood ependymoma, follow-up, relapse, surveillance, Medicine, Humans, Prospective Studies, Prospective cohort study, Child, Preschool, Survival rate, business.industry, Brain Neoplasms, Childhood ependymoma, Follow-up, Re-irradiation, Relapse, Surveillance, Child, Preschool, Female, Follow-Up Studies, Magnetic Resonance Imaging, Neoplasm Recurrence, Local, Prognosis, Retrospective cohort study, medicine.disease, Minimal residual disease, Clinical trial, Neoplasm Recurrence, Neurology, Oncology, Local, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, 030220 oncology & carcinogenesis, Concomitant, Neurology (clinical), business, 030217 neurology & neurosurgery, Cohort study
Abstract: Purpose: The aims of patients’ radiological surveillance are to: ascertain relapse; apply second-line therapy; accrue patients in phase 1/2 protocols if second-line therapy is not standardized/curative; and assess/treat iatrogenic effects. To lessen the emotional and socioeconomic burdens for patients and families, we ideally need to establish whether scheduled radiological surveillance gives patients a better outcome than waiting for symptoms and signs to appear. Methods: We analyzed a prospective series of 160 newly-diagnosed and treated pediatric/adolescent patients with intracranial ependymoma, comparing patients with recurrent disease identified on scheduled MRI (the RECPT group; 34 cases) with those showing signs/symptoms of recurrent disease (the SYMPPT group; 16 cases). The median follow-up was 67 months. Results: No significant differences emerged between the two groups in terms of gender, age, tumor grade/site, shunting, residual disease, or type of relapse (local, distant, or concomitant). The time to relapse (median 19 months; range 5–104) and the MRI follow-up intervals did not differ between the SYMPPT and RECPT groups. The presence of signs/symptoms was an unfavorable factor for overall survival (OS) after recurrence (5-year OS: 8% vs. 37%, p = 0.001). On multivariable analysis, an adjusted model confirmed a significantly worse OS in the SYMPPT than in the RECPT patients. Conclusions: Symptomatic relapses carried a significantly worse survival for ependymoma patients than recurrences detected by MRI alone. It would therefore be desirable to identify recurrences before symptoms develop. Radiological follow-up should be retained in ependymoma patient surveillance because there is a chance of salvage treatment for relapses found on MRI
Published: 2018

48. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Author: Carlo Giussani, Paola Peretta, Daniele Bertin, Piergiorgio Modena, E. Schiavello, Maura Massimino, Ermanno Giombelli, Laura Valentini, Rosalba Miceli, Maria Luisa Garrè, Luna Boschetti, P Bertolini, Giuseppina Calareso, Lorenza Gandola, Salvina Barra, Paolo Ferroli, Barbara Diletto, Giuseppe Cinalli, Veronica Biassoni, Annamaria Buccoliero, Felice Giangaspero, Lucia Quaglietta, Maurizio Mascarin, Angela Mastronuzzi, Milena La Spina, Elisabetta Viscardi, Carlo Efisio Marras, Anna Mussano, Giovanni Scarzello, Armando Cama, Emilia Pecori, Bianca Pollo, Iacopo Sardi, Rita Balter, Francesca R. Buttarelli, Manila Antonelli, Silvia Scoccianti, Lorenzo Genitori, Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, and Gandola, L
Subjects: Male, Ependymoma, Cancer Research, medicine.medical_treatment, Kaplan-Meier Estimate, Neurosurgical Procedures, surgery, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Child, Prospective cohort study, Adjuvant, Etoposide, grade, Brain Neoplasms, boost, ependymoma, prognosis, Chemoradiotherapy, Chemotherapy regimen, Treatment Outcome, Oncology, Vincristine, Child, Preschool, 030220 oncology & carcinogenesis, Female, prognosi, medicine.drug, medicine.medical_specialty, Adolescent, Cyclophosphamide, Disease-Free Survival, 03 medical and health sciences, medicine, Humans, Clinical Investigation, Progression-free survival, Preschool, Radiotherapy, business.industry, Infant, Chemoradiotherapy, Adjuvant, medicine.disease, Surgery, Radiation therapy, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract: Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
Published: 2016

49. EWING SARCOMA OF THE BONE IN CHILDREN UNDER 6 YEARS OF AGE

Author: Antonio Perez Martinez, Maria Antonietta De Ioris, Arcangelo, Prete, Raffaele, Cozza, Marta, Podda, Carla, Manzitti, Andrea, Pession, Elisabetta, Schiavello, Benedetta, Contoli, Rita, Balter, Franca, Fagioli, Bisogno, Gianni, Loredana, Amoroso, Franco, Locatelli, Roberto, Luksch, De Ioris MA, Prete A, Cozza R, Podda M, Manzitti C, Pession A, Schiavello E, Contoli B, Balter R, Fagioli F, Bisogno G, Amoroso L, Locatelli F, and Luksch R.
Subjects: Male, Genetics and Molecular Biology (all), medicine.medical_treatment, Cancer Treatment, lcsh:Medicine, Kaplan-Meier Estimate, Pediatrics, Biochemistry, Metastasis, Surgical oncology, Basic Cancer Research, Bone and Soft Tissue Sarcomas, lcsh:Science, Child, Multidisciplinary, Sarcoma, Combined Modality Therapy, Oncology, Italy, Child, Preschool, Medicine, Female, Research Article, medicine.medical_specialty, Ewing Sarcoma, Bone Neoplasms, Sarcoma, Ewing, Disease-Free Survival, Humans, Infant, Proportional Hazards Models, Biochemistry, Genetics and Molecular Biology (all), Agricultural and Biological Sciences (all), Ewing, Internal medicine, medicine, Preschool, Chemotherapy, PROGNOSTIC-FACTORS, FAMILY TUMORS, IFOSFAMIDE, ETOPOSIDE, CYCLOPHOSPHAMIDE, OSTEOSARCOMA, CHEMOTHERAPY, EXPERIENCE, YOUNGER, IMPACT, Proportional hazards model, business.industry, lcsh:R, Cancers and Neoplasms, medicine.disease, Confidence interval, Surgery, Radiation therapy, Pediatric Oncology, Localized disease, lcsh:Q, business
Abstract: Background Ewing Sarcoma Family Tumours (ESFT) are rare in early childhood. The aim of this study was to report the clinical characteristics and outcome of children under 6 years of age affected by ESFT of the bone in Italy. Methods The records of all the children diagnosed with osseous ESFT in centres members of the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) from 1990 to 2008 were reviewed. The Kaplan–Meier method was used for estimating overall and progression-free survival (OS, PFS) curves; multivariate analyses were performed using Cox proportional hazards regression model. Results This study includes 62 patients. An axial primary localization was present in 66% of patients, with the primary site in the chest wall in 34%. Fourteen (23%) patients presented metastatic disease. The 5-year OS and PFS were 73% (95% confidence interval, CI, 58–83%) and 72% (95% CI 57–83%) for patients with localized disease and 38% (95% CI 17–60%) and 21% (95% CI 5–45%) for patients with metastatic disease. Metastatic spread, skull/pelvis/spine primary localization, progression during treatment and no surgery predicted worse survival (P
Published: 2013

50. Foreign patients and multicultural challenges in pediatric oncology: The experience of the Istituto Nazionale dei Tumori in Milan.

Author: Lombardi M, Silva M, Giovanetti M, Cabibbe D, Luksch R, Terenziani M, Casanova M, Spreafico F, Meazza C, Podda M, Biassoni V, Schiavello E, Chiaravalli S, Puma N, Bergamaschi L, Gattuso G, Nigro O, Sironi G, Colombo V, Ferrari A, Massimino M, and Clerici CA
Subjects: Humans, Italy, Child, Female, Male, Adolescent, Child, Preschool, Infant, Medical Oncology, Cultural Diversity, Emigrants and Immigrants, Neoplasms therapy
Abstract: This paper describes the complexity of the clinical management of foreign minors suffering from cancer, through the clinical experience of an Italian referral center. The study includes 50 patients less than 18 years (22% of the patients admitted to the unit in 2023), 32 foreigners who were Italian resident and 18 who had come to Italy specifically to receive cancer treatment. Patients who migrate for healthcare reasons often arrive at the referral center with advanced disease or relapse. Numerous socio-cultural issues were reported. To address them, specific strategies were implemented to ensure equal and high-quality care for all patients, respecting their needs., (© 2024 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

157 results on '"Schiavello E"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources